Yahoo partner profiller

Yahoo! JAPANが提供する国内最大級の出会い応援サイト。24時間の監視体制やプロフィール審査、安全なシステムでまじめな恋活・婚活を全力サポートします。まずは簡単な無料の利用登録で興味のある相手を探してみよう! See the company profile for Enterprise Products Partners L. (EPD) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ... Yahoo makes it easy to enjoy what matters most in your world. Best in class Yahoo Mail, breaking local, national and global news, finance, sports, music, movies and more. You get more out of the web, you get more out of life. The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web. News, email and search are just the beginning. Discover more every day. Find your yodel. Take a trip into an upgraded, more organized inbox. Sign in and start exploring all the free, organizational tools for your email. Check out new themes, send GIFs, find every photo you’ve ever sent or received, and search your account faster than ever. Mindhunter, season 2, Netflix, review: A fascinating, remarkable show you'll want to binge in one go The Telegraph via Yahoo News · 1 year ago. The blockbuster success of season one of David Fincher’s Mindhunter was a reminder that serial... Kanye West Declares Himself ‘New Moses,’ Says He Won’t Release New Music Till Freed From Universal and Sony/ATV Deals. Kanye West took a break from his presidential campaign to make some declarations about his music career Monday, saying that he will refuse to release any new music until his record company, Universal Music Group, and his publisher, Sony/ATV Music Publishing, free him ... 1. Cari partner untuk melakukan latihan. Anda memang bisa melakukan semua latihan yang sudah dibahas di atas sendirian. Tapi akan jauh lebih menyenangkan jika Anda mempunyai partner latihan, entah itu teman, kakak, adik atau bahkan guru Anda. Banyak keuntungan berlatih dengan partner. Jika dia lebih berpengalaman, Anda akan lebih mudah belajar ... Find out quickly, easily, and effortlessly boyfriend, husband, wife or someone you know is active on other dating sites and playing you. With a simple email search, Profile Searcher will improve the odds by searching over 100 major paid and free dating sites for profiles of anyone you are interested in or already in a relationship with

USPS Board Chairman Revealed as Director of Mitch McConnell, Trump-Linked Super PACs

2020.09.01 02:24 3ustice3 USPS Board Chairman Revealed as Director of Mitch McConnell, Trump-Linked Super PACs

https://truthout.org/articles/usps-board-chairman-revealed-as-director-of-mcconnell-trump-linked-super-pacs/
USPS Board of Governors Chairman Robert M. Duncan is listed as Director of Mitch McConnell's $130M super PAC, Senate Leadership Fund. https://cis.scc.virginia.gov/EntitySearch/BusinessInformation?businessId=298522&source=FromEntityResult&isSeries=False
North Rock Reports, LLC (US and offshore companies)
OpenCorporates - The Open Database Of The Corporate World
Senate Leadership Fund (Virginia) https://opencorporates.com/companies/us_va/07951544
North Rock Reports, LLC (Virginia) https://opencorporates.com/companies/us_va/S3151224
OFFHSORE LEAKS DATABASE
North Rock Reports, LLC https://offshoreleaks.icij.org/search?c=USA&cat=4&d=&e=&j=&q=North+Rock+Reports%2C+LLC&utf8=%E2%9C%93
Genpact (NYSE: G) is a global professional services firm running thousands of processes primarily for Global Fortune 500 companies.
Genpact LLC (NYSE) G Connected to offshore entities in Bermuda https://offshoreleaks.icij.org/nodes/80069070
The Open Database Of The Corporate World - US and offshore companies
GENPACT GLOBAL BERMUDA LIMITED CORPORATION (New Jersey (US) https://opencorporates.com/companies/us_nj/0450508326
Genpact Global (Bermuda) Limited (Pennsylvania (US) https://opencorporates.com/companies/us_pa/6949212
Genpact Global (Bermuda) Limited Cont'd https://opencorporates.com/companies/bm/40416
Genpact Global Holdings (Bermuda) Limited https://opencorporates.com/companies/bm/40417
In Weird Twist, Russians Sue American Firms For IP Theft https://www.forbes.com/sites/kenrapoza/2020/08/31/in-weird-twist-russians-sue-american-firms-for-ip-theft/#7d66ada2241e
F5 Networks Inc NASDAQ: (FFIV) https://www.bloomberg.com/profile/company/FFIV*:MM
Lynwood Investments Sues F5 Networks Over Popular NGINX Web Server Software Used by 450 Million Websites Globally https://www.prnewswire.com/news-releases/lynwood-investments-sues-f5-networks-over-popular-nginx-web-server-software-used-by-450-million-websites-globally-301072683.html
Columbia Georgia Intermediate Municipal Bond Fund Class C Nasdaq (NGINX) https://finance.yahoo.com/quote/NGINX/
OpenCorporates - The Open Database Of The Corporate World
F5 Networks Inc (US) NASDAQ: (FFIV) https://opencorporates.com/companies?utf8=%E2%9C%93&q=F5+Networks+Inc&commit=Go&jurisdiction_code=&utf8=%E2%9C%93&controller=searches&action=search_companies&inactive=false&order=
LYNWOOD INVESTMENTS CY LIMITED (Cyprus) https://opencorporates.com/companies/cy/HE159138
Runa Capital Inc (Russian owned) https://www.bloomberg.com/profile/company/8373389Z:US
Runa Capital Inc (US) 4 companies found see below
RUNA CAPITAL III (GP) BRANCH (California) https://opencorporates.com/companies/us_ca/C4268121
RUNA CAPITAL INC BRANCH (Florida) https://opencorporates.com/companies/us_fl/F20000000223
RUNA CAPITAL, INC. (Delaware) https://opencorporates.com/companies/us_de/5191933
RUNA CAPITAL, INC. BRANCH (California) https://opencorporates.com/companies/us_ca/C3805275
EVENTURE CAPITAL PARTNERS II LLC (Delaware) https://opencorporates.com/companies/us_de/4994445
EVENTURE CAPITAL PARTNERS II LLC BRANCH (California) https://opencorporates.com/companies/us_ca/201125610348
OFFSHORE LEAKS DATABASE
EVENTURE CAPITAL PARTNERS II LLC (United States) https://offshoreleaks.icij.org/search?c=USA&cat=4&d=&e=&j=&q=+EVENTURE+CAPITAL+PARTNERS+II+LLC&utf8=%E2%9C%93
Genpact (NYSE: G) is a global professional services firm running thousands of processes primarily for Global Fortune 500 companies.
Genpact LLC (NYSE) G Connected to offshore entities in Bermuda https://offshoreleaks.icij.org/nodes/80069070
The Open Database Of The Corporate World - US and offshore companies
GENPACT GLOBAL BERMUDA LIMITED CORPORATION (New Jersey (US) https://opencorporates.com/companies/us_nj/0450508326
Genpact Global (Bermuda) Limited (Pennsylvania (US) https://opencorporates.com/companies/us_pa/6949212
Genpact Global (Bermuda) Limited Cont'd https://opencorporates.com/companies/bm/40416
Genpact Global Holdings (Bermuda) Limited https://opencorporates.com/companies/bm/40417
submitted by 3ustice3 to NewMexico [link] [comments]


2020.09.01 02:23 3ustice3 Nevada: USPS Board Chairman Revealed as Director of Mitch McConnell, Trump-Linked Super PACs

https://truthout.org/articles/usps-board-chairman-revealed-as-director-of-mcconnell-trump-linked-super-pacs/
USPS Board of Governors Chairman Robert M. Duncan is listed as Director of Mitch McConnell's $130M super PAC, Senate Leadership Fund. https://cis.scc.virginia.gov/EntitySearch/BusinessInformation?businessId=298522&source=FromEntityResult&isSeries=False
North Rock Reports, LLC (US and offshore companies)
OpenCorporates - The Open Database Of The Corporate World
Senate Leadership Fund (Virginia) https://opencorporates.com/companies/us_va/07951544
North Rock Reports, LLC (Virginia) https://opencorporates.com/companies/us_va/S3151224
OFFHSORE LEAKS DATABASE
North Rock Reports, LLC https://offshoreleaks.icij.org/search?c=USA&cat=4&d=&e=&j=&q=North+Rock+Reports%2C+LLC&utf8=%E2%9C%93
Genpact (NYSE: G) is a global professional services firm running thousands of processes primarily for Global Fortune 500 companies.
Genpact LLC (NYSE) G Connected to offshore entities in Bermuda https://offshoreleaks.icij.org/nodes/80069070
The Open Database Of The Corporate World - US and offshore companies
GENPACT GLOBAL BERMUDA LIMITED CORPORATION (New Jersey (US) https://opencorporates.com/companies/us_nj/0450508326
Genpact Global (Bermuda) Limited (Pennsylvania (US) https://opencorporates.com/companies/us_pa/6949212
Genpact Global (Bermuda) Limited Cont'd https://opencorporates.com/companies/bm/40416
Genpact Global Holdings (Bermuda) Limited https://opencorporates.com/companies/bm/40417
In Weird Twist, Russians Sue American Firms For IP Theft https://www.forbes.com/sites/kenrapoza/2020/08/31/in-weird-twist-russians-sue-american-firms-for-ip-theft/#7d66ada2241e
F5 Networks Inc NASDAQ: (FFIV) https://www.bloomberg.com/profile/company/FFIV*:MM
Lynwood Investments Sues F5 Networks Over Popular NGINX Web Server Software Used by 450 Million Websites Globally https://www.prnewswire.com/news-releases/lynwood-investments-sues-f5-networks-over-popular-nginx-web-server-software-used-by-450-million-websites-globally-301072683.html
Columbia Georgia Intermediate Municipal Bond Fund Class C Nasdaq (NGINX) https://finance.yahoo.com/quote/NGINX/
OpenCorporates - The Open Database Of The Corporate World
F5 Networks Inc (US) NASDAQ: (FFIV) https://opencorporates.com/companies?utf8=%E2%9C%93&q=F5+Networks+Inc&commit=Go&jurisdiction_code=&utf8=%E2%9C%93&controller=searches&action=search_companies&inactive=false&order=
LYNWOOD INVESTMENTS CY LIMITED (Cyprus) https://opencorporates.com/companies/cy/HE159138
Runa Capital Inc (Russian owned) https://www.bloomberg.com/profile/company/8373389Z:US
Runa Capital Inc (US) 4 companies found see below
RUNA CAPITAL III (GP) BRANCH (California) https://opencorporates.com/companies/us_ca/C4268121
RUNA CAPITAL INC BRANCH (Florida) https://opencorporates.com/companies/us_fl/F20000000223
RUNA CAPITAL, INC. (Delaware) https://opencorporates.com/companies/us_de/5191933
RUNA CAPITAL, INC. BRANCH (California) https://opencorporates.com/companies/us_ca/C3805275
EVENTURE CAPITAL PARTNERS II LLC (Delaware) https://opencorporates.com/companies/us_de/4994445
EVENTURE CAPITAL PARTNERS II LLC BRANCH (California) https://opencorporates.com/companies/us_ca/201125610348
OFFSHORE LEAKS DATABASE
EVENTURE CAPITAL PARTNERS II LLC (United States) https://offshoreleaks.icij.org/search?c=USA&cat=4&d=&e=&j=&q=+EVENTURE+CAPITAL+PARTNERS+II+LLC&utf8=%E2%9C%93
Genpact (NYSE: G) is a global professional services firm running thousands of processes primarily for Global Fortune 500 companies.
Genpact LLC (NYSE) G Connected to offshore entities in Bermuda https://offshoreleaks.icij.org/nodes/80069070
The Open Database Of The Corporate World - US and offshore companies
GENPACT GLOBAL BERMUDA LIMITED CORPORATION (New Jersey (US) https://opencorporates.com/companies/us_nj/0450508326
Genpact Global (Bermuda) Limited (Pennsylvania (US) https://opencorporates.com/companies/us_pa/6949212
Genpact Global (Bermuda) Limited Cont'd https://opencorporates.com/companies/bm/40416
Genpact Global Holdings (Bermuda) Limited https://opencorporates.com/companies/bm/40417
submitted by 3ustice3 to Nevada [link] [comments]


2020.08.31 18:23 Davidssvr 3 Ways to Spy on Cheating Spouse Phone

3 Ways to Spy on Cheating Spouse Phone
How does one understand if your husband or married person is cheating? If you found this text as a result of the search question you typewritten, then you want to possibly already suspect that you’re managing AN unfaithful partner, or at the terribly least that one thing is amiss in your relationship. The signs of unfaithfulness look totally different in each relationship, of course, however, there are some common threads that you just will rummage around for. 1st and foremost, I will be able to tell you this: If your gut tells you that your partner is cheating, chances area unit likelihood is that you are just right. That said, you'll wish to collect alternative proof before you confront your wife concerning their behavior. Common signs of unfaithfulness that you just may wish to seem for include:

1.Improved Appearance.

If your wife suddenly starts to workout and uptake healthier, that would be a symptom that they're making an attempt to look additional engaging to somebody (possibly you, however presumably AN affair partner). If Mr. Sweatpants-Are-Just-Fine-at-a-Party starts carrying slacks with matching socks and a trendy shirt, or Ms. I-Can’t-Help-It-If-I-Smell-Like-Our-Son’s-Poopy-Diapers suddenly smells like Chanel No. 5, which will indicate AN affair. Ditto for a replacement haircut and new undergarment — particularly if your wife's appearance is identical around you, however considerably higher for work or sure social events.

2. Secretive Phone or PC Use.

Cheaters tend to use their phones and computers additional ofttimes than before and to protect them as if their lives depend upon it. If your partner’s phone and laptop computer ne'er needed a secret before, and currently they are doing, that’s not a decent sign. If your partner suddenly starts deleting texts and clearing their browser history on each day, that’s not a decent sign. If your partner ne'er relinquishes possession of their phone, even taking it into the lavatory once they shower, that’s not a decent sign. If you raise to review your partner’s phone, and they say no, that’s conjointly a retardant. Honestly, what might presumably be there — apart from info concerning your surprise birthday — that they'd wish to stay secret?

3. Periods once Your Spouse is unapproachable.

If your partner is cheating on you, they're less possible to answer your calls and reply to your texts. you'll hear legitimate-sounding excuses like they were in a very meeting, they were driving, they were in a very “dead zone” and didn’t understand you were making an attempt to induce contact. If your partner is unapproachable whereas operating late or on a business trip, that’s a nasty sign.

https://www.knowhowto.tech

How to Catch Cheating Spouse by Spying on Phone

To be honest, there’s typically no reason to justify spying on your partner or wife. Not solely as a result of marriages and relationships an area unit meant to be designed on ‘trust’ and ‘mutual respect’ and ‘honesty’, however, if not properly done, you’ll most likely be caught guilty. If the moral implications aren’t enough to advise you, then the prospect of being within their phone, red-faced and frantically swiping through their texts whereas muttering expletives to yourself, might.
But what if you don’t care concerning getting caught? What if you don’t care concerning ‘trust’ or ‘mutual respect’ or ‘being an honest person’? What if you’re a hundred percent convinced? Then you'll strive one in all these useful solutions to trace them down and corner them just like the rats they're.

DataBurglar

For our spurned readers from Britain, Australia, South-East Asia, America, Europe, and everyone over the planet, here’s DataBurglar, an observance app/spy computer code that enables couples to monitor their spouses' activities to understand if they're being unfaithful or not. verify if your partner is concealing one thing from you or if they're lying to you concerning one thing. What, exactly, will this entail?
Using the DataBurglar spy app, you'll gain access and track your spouse’s phone call, call log, social media activity, address book contacts, Skype calls, and text messages remotely, while not having to break your partner’s phone or install it directly on their device. DataBurglar conjointly permits you to gain access to all or any access to recent and deleted chat, messages, and information that is able to alter you and catch unfaithful partners red-handed even once they try and delete proof of unfaithfulness.
Using [[email protected]](mailto:[email protected]), you may be ready to spy any cell phone; spy on iPhone moreover as golem phone, and have device access while not having to travel through the strain of putting in the app yourself. Everything is completed remotely, simply send a call for participation to [[email protected]](mailto:[email protected]) or visit - www.knowhowto.tech

Hire a professional

Another way to catch a cheating spouse on the phone is by hiring an expert to assist you investigate. Hiring AN professional is another definite thanks to verifying the reality, and catch a cheating partner within the act. All you've got to try and do is to contact one in all these verified guys to assist you to monitor the digital activity of your partner, thus you'll check their calls, texts, Facebook activity, and GPS location, and much additional.
Hiring a professional helps keep track of mobile & web usage, monitor activities moreover as communications. Having the flexibility to trace things like SMS messages, emails, internet browsing, and phone calls, you may perpetually be up to this point with what's happening. All this info is handily delivered straight to your internet account! Their ground-breaking computer code can assist you to unlock reality and supply you with the answers you've been trying to find.

Couple Monitoring App

Couple Tracking App is like equal rights spying. Each partner should comply with permit their digital activity to be monitored, thus you guys will check every other’s calls, texts, Facebook activity, and GPS location from afar. To request Couple following App, send AN email to [[email protected]](mailto:[email protected])
There’s one catch, though: You and your partner solely have access to the primary thirty characters of every other’s texts, and you'll solely track your GPS locations at intervals of 30-minute intervals. that may seem to be a fairly minor caveat, however, those who wish to cheat tend to work out some way to try and do it in spite of the obstacles, thus don’t be shocked if you see your married person sends out a message like, “Hey Alex are you able to grab the McAllister file I believe I left it at my table before.
If you're trying to find some way to catch a cheating partner by spying on their phone, victimization one in all the 3 ways listed above is the way to go.
submitted by Davidssvr to u/Davidssvr [link] [comments]


2020.08.27 00:38 soggybread Investment Thesis: Why investing in POW.TO (Power Corporation of Canada) now is an investment in a future high market cap Wealthsimple IPO

I have seen some posts here wondering about the wisdom of investing in Wealthsimple's parent company, Power Corporation of Canada (POW.TO). I decided to look more into this, decided to post my investment thesis and research on why I, long-term, I have a very bullish view on Wealthsimple (and by extension POW.TO), and why I think this is equal to being an early stage investor in a Wealthsimple IPO.

Overview

Current Products

Investment Rounds

WS has had many successful rounds of funding and a vote of confidence from both its parent POW.TO and other multinationals investing in fintech.

Growth

WS has been extremely aggressive in targeting growth areas. Wealthsimple’s CEO Mike Katchen has said he wants to position the company as a “full-stack” financial services company. Here are some of their current expansion areas:

People

WS is run by young guys who have big ambitions and plans for the company. Sometimes there are CEOs with the intangibles that can really drive a company's growth, and from what I can glean, I think the company has a lot of potential here in terms of vision by its leaders. You can read more about the founders here
Quote sfrom CEO: Michael Katchen
On being laughed out of the boardroom when he proposed his idea for Wealthsimple:
Within the last month, Wealthsimple has also opened an office in London. Katchen said a push into the European market is “possible” as its “ambitions are global,” but right now the Canadian and U.S. markets are “a lot to chew.” It is a far cry from the company’s early days: Katchen said he was “laughed out of the boardroom” for laying out a global vision for Wealthsimple at a time when they had just $1.9-million in funding and 20 users***.***“It’s a very personal mission of mine since I moved back from California, to inspire more Canadian companies to think big and to think internationally about the businesses that they’re building,” he said. (reference)
On Wealthsimple's growth in the next 10-15 years:
Wealthsimple has more than $5 billion in assets under management and 175,000 customers in Canada, the U.S. and U.K. He sees that reaching $1 trillion 15 years. “We’re just getting started,” he said. “Our plans are to get to millions of clients in the next five years.” (reference)

Brand Value and Design

Out of all the financial services company in Canada, WS probably has the most cohesive and smart design concept across its platforms and products. I see the value in Wealthsimple in not just the assets they have under management, but also the value of the brand itself. I mean, what kind of financial services company makes a blog post about their branding colour scheme and font choices? Also see: Wealthsimple’s advertisement earlier this year capturing 4 million views on Youtube.
There also seems to be very strong brand awareness and brand loyalty amongst its users. I think a lot of users find WS refreshing as a financial services company because they cut through the "bullshit" and legalese, and try to simply things for the consumer. They also have their own in house team of designers and creative directors to do branding, design, and advertising, and this kind of vertical integration is generally unheard of in the financial services industry (reference).

Potential IPO?

Interestingly, the CEO’s ultimate goal is to take the company public. Therefore, I see an investment in POW.TO as being an early stage pre-IPO investor in WS (reference).
The goal is to get Wealthsimple to the size and scale to go public, something that Katchen said he’s “obsessed with.” While admitting that an IPO was still a few years down the road, Katchen already has a target of $20 billion in assets under administration (AUA) as the tipping point (the company recently announced $4.3 billion in AUA as of Q1 2019) (reference)

Future Potential

Ultimately, my sense is that a spun-out Wealthsimple IPO eventually be worth a lot, perhaps even more than POW.TO at some point. Obviously the company is losing money right now, and no where even close to an IPO, and there are still many chances that this company could flop. The best analogy that I can think of is when Yahoo bought an early stake in Alibaba (BABA) back in the early 2000s, and there came a point where their stake in BABA was worth more than Yahoo’s core business. I think an investment in POW.TO now is an early investment in WS before it goes public. (reference)

Risks

The X Factor

What I find particularly compelling about WS is they have aggressively positioned themselves to be a disruptor in the Canadian financial services industry. This is an area that has traditionally been thought to be a firewall for the Big Five Banks. There is also a generational gap in investing approaches, knowledge, and strategy, and I think WS has positioned itself nicely with first-time investors. My sense is that COVID-19 has also captured a huge amount of young adults with its trading app in the last few months, who will continue to use Wealthsimple products in the future. The average age of its user is around 34. As younger individuals are more comfortable with moving away traditional banking products, I think Wealthsimple’s product offering offers significant advantages over its competitors.

Power Corp is a Good Home

Currently POW.TO is trading at $26.30, down from its 52-week high of $35.15. I see an investment in POW.TO now as fairly low risk, and while WS grows, and there is also the added benefit of a high dividend stock. One of the most confusing things I found about Power Corp was its confusing corporate structure where there were two stocks, Power Financial Corp, and Power Corp of Canada. Fortunately, in Dec 2019, they simplified and consolidated the stocks, which also simplifies the holding structure of WS. I currently see POW.TO has a good stock to hold as well if you're a dividend holder, with a dividend of 6.86%.
Also, POW.TO is patient enough to bide its time and let its investment in WS grow, unlike a VC that might want to sell it quick. For example, the reason why WS went with POW.TO instead of the traditional VC route is explained here:
Katchen has directly addressed the question of why he did not go the traditional VC route recently, saying: If you are a business that requires perhaps decades to achieve the vision you have, well, if you’re not going to be able to generate the kind of returns that venture needs is they will force you to sell yourself, they will force you to go public before you’re ready, or they will just forget about you because you’re going to be a write off. And so Katchen essentially flipped Wealthsimple to Power Financial. Power is well known as a conservative, patient, long-term investor. (https://opmwars.substack.com/p/the-wealthsimple-founders-before)
My belief is there is a huge unrecognized potential in POW.TO's massive ownership stake in WS that will be realized maybe 5-10 years down the road. I didn't really dive into the financials of POW.TO in relation to WS's performance, because the earnings reports do no actually say much about WS. I'm aware of the main criticisms that POW.TO is a mature company and dividend stock that has been trading sideways for many years, and the fact that WS is currently not a profitable company. I am not a professional investor, and this is just my amateur research, so I certainly welcome any comments/criticism of this thesis that people on this subreddit might have! (Please be gentle on me!).

Other Readings

- https://betakit.com/wealthsimple-raises-100-million-from-allianz-x-to-build-a-full-stack-financial-service/
- https://betakit.com/power-financial-claims-89-percent-stake-in-wealthsimple-following-new-30-million-investment/
- https://www.powercorporation.com/media/uploads/reports/quartepcc-2020-q2-eng_3KVPXLd.pdf

Edit: Thanks to all for the thoughtful comments about POW's size and other holdings relative to WS, and that WS is basically a tiny, tiny portion of POW.TO. Again, I am just an amateur investor, appreciate we can discuss these points on this forum! And fair point is taken that WS's margins are also razor thin right now. I guess I am buying more into the CEO's vision of growth (see this video about his confidence about getting to $1 trillion AUM (!) in the next 8 years), rather than the current financial status or size of the company. Call me delusional if you will :P.
In any case, glad that I was able to flush out these thoughts with the CanadianInvestor community! I do wonder if WS's expansion into a broad-based financial services company (into mortgages, credit lines, and life insurance) might increase their profitability and size over time. https://www.bnnbloomberg.ca/wealthsimple-targets-canada-s-richest-with-grayhawk-partnership-1.1301993
submitted by soggybread to CanadianInvestor [link] [comments]


2020.08.17 18:36 PradoMV96 A thorough DD on $AQST (Aquestive Therapeutics)

What is $AQST? * Aquestive is a pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives * Their initial focus, supported by their current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.
What are their current Products? * Overview of their marketed & licensed Products * They currently have one product on the market: * It is Sympazan * They also have two licensed products & they are: * Suboxone * Zuplenz * Link
What are their current Pipelines? * They currently have multiple pipelines in the works & they are: * AQST-108: It's an epinephrine * It's intended use is to treat anaphylaxis * Currently in Phase 1 trials * AQST-305: it's an octreotide * It's intended use is to treat carcinoid syndrome * Currently in preclinical trials * Libervant: it's a diazepam * It's intended use is for seizures & cluster seizures * FDA accepted NDA submission in Feb 2020. $AQST is currently seeking a partner outside of USA * Link
What is their PharmaFilm Technology? * Link * PharmFilm is a unique and versatile technology for high-performance drug delivery. Aquestive scientists combine the customizable features of PharmFilm with patented formulation and engineering processes to optimize the delivery of active pharmaceutical ingredients (APIs). * There are three delivery methods for their PharmaFilm Tech: * Buccal: Controlled release and engineered retention time in a controlled microenvironment * Sublingual: Rapid onset of action with direct entry into systemic circulation * Lingual: Rapid disintegration and controlled release with bioequivalancy to tablets and capsules
How does PharmaFilm work? * Polymers are used as film formers to hold the API and excipients in place * Patented techniques are used to ensure that the API is uniformly distributed throughout the film. * Aquestive utilizes the proprietary features of PharmFilm® technology along with a wide array of solvents, pH modifiers, and permeation enhancers to achieve target absorption, bioavailability, and onset of action. * The proprietary compositional profiles of oral films delivered with PharmFilm can be tailored to the buccal or sublingual microenvironment in order to achieve a desired rate of absorption. Aquestive’s formulation team uses the technology’s adaptable polymer matrix, along with FDA-approved permeation enhancers and novel solvent systems to help improve the bioavailability of an active pharmaceutical ingredient (API) and the speed at which it is released to the mucosa.This makes film a viable delivery platform for a wide range of molecules, including those with low solubility (BCS Class II) or low bioavailability (BCS Class IV) as well as molecules that are highly soluble. * Link
Corporate Presentation (August 2020) * Link to the presentation * AQST-108; solving problems in anaphylaxis: * Oral sublingual film formulation of epinephrine for the treatment of allergic reactions (Type 1), including anaphylaxis * Phase 1 dose escalation proof-of-concept study in healthy subjects demonstrated ability to deliver systemic epinephrine using proprietary PharmFilm® technologies * At constructive pre-IND meeting held on February 4, 2020, FDA confirmed clinical development will be reviewed under the regulatory 505(b)(2) pathway as proposed by Aquestive * FDA completed safety review of IND in July 2020 and approved commencement of first planned PK trial * Received Fast Track Designation by the FDA * Financial Summary: * Current capital position adequate into early 2021 * Launched process for potential monetization of anticipated royalties associated with Sunovion’s KYNMOBI that received FDA approval in May 2020 * Second quarter 2020 total revenues of $21.7 million * There's a lot more detailed information that is also presented nicely in their corporate Presentation that I highly suggest you read
Recent Financials/business updates * As of June 30, 2020, cash and cash equivalents were $25.4 million * Aquestive’s net loss for the second quarter 2020 was $2.3 million, or $0.07 loss per share. The net loss for the second quarter 2019 was $20.5 million, or $0.82 loss per share * Total revenues were $21.7 million in the second quarter 2020, compared to $11.1 million in the second quarter 2019 * This year-over-year increase reflected license fees and royalty revenue in the second quarter of 2020 primarily related to $12 million recognized as a result of the KYNMOBI approval, of which $8 million is non-cash revenue related to minimum royalties that will be received over future years * Generated 59% year-over-year revenue growth for Sympazan * Total revenues of approximately $35 million to $45 million * Continues to advance Libervant™ (diazepam) through FDA review and on-going inspection process of manufacturing and clinical investigational sites * FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokinetics (PK) clinical trials * Ongoing process for potential monetization of royalty rights in KYNMOBI™ (apomorphine) continues * Re-affirms full year 2020 financial guidance
Negatives/risks of the business * As found on their recent 10-K Filings: * "We will need substantial additional capital to fund our operations, which may not be available on acceptable terms, if at all." * "We may sell additional equity, incur debt or raise funds through licensing arrangements to fund our operations, which may result in dilution to our stockholders, impose restrictions on our business or require us to relinquish proprietary rights" * "We are dependent upon the commercial success of our licensed and self-commercialized products and other licensing activities to generate revenue for the near future" * "A substantial portion of our revenues is derived from a single customer and license and any loss or material reduction in revenues from such significant customer would adversely affect our business." * "While we continue to plan to seek to monetize our drug product Apomorphine, there is no assurance that we will be able to monetize our drug product candidate Apomorphine in the amount or at the time we have planned, or at all, which, if this were to occur, would have a material adverse impact on our financial position and capital needs." * "We will be required to demonstrate to the FDA that our drug candidate Libervant® provides a “major contribution to patient care” relative to the approved drugs with the same active moiety for the same indication, and there can be no assurance that we will be successful." * "have directly marketed just a single product, Sympazan, and that effort is in its very early stages after being only recently launched. With this limited experience, we may lack the necessary expertise, personnel and resources to successfully commercialize this product or our other products that must first receive regulatory approval, either on our own or together with collaborators." * "If we are unable to successfully establish strong capabilities in sales, marketing, and distribution for our approved products, we may not be successful in commercializing our products if and when they obtain regulatory approved" * "Our commercial success depends upon attaining significant market acceptance of our products and product candidates, if approved, among patients, physicians, pharmacists and the medical community" * "Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any." * "We face significant competition from other pharmaceutical companies, and our operating results will suffer if we fail to compete effectively." * "We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed." * "We rely on limited sources of supply for our thin film foil, and any disruption in the chain of supply may impact production and sales and cause delay in developing and commercializing our proprietary PharmFilm® Technology product candidates." * 10-K
Events to positively impact the rest of 2020 * On December 2nd 2019, $AQST Announced the completion, as planned, of the rolling submission of a New Drug Application (NDA) to the FDA for its therapeutic candidate Libervant (diazepam) Buccal Film for the management of seizure clusters. Libervant has received orphan drug designation from the FDA * On February 6th 2020, $AQST Announced that it had a constructive face-to-face pre-Investigational New Drug (IND) Application meeting with the FDA for its drug candidate, AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm technologies. * On February 10th 2020, $AQST Announcedthat the FDA accepted the Company’s NDA for Libervant (diazepam) Buccal Film for the management of seizure clusters. The FDA has assigned a PDUFA goal date of September 27, 2020. If approved by the FDA, Libervant will be the first oral diazepam-based therapy approved for management of seizure clusters in the population of 1.2 million refractory epilepsy patients. * On May 5th 2020, $AQST Announced that AQST-108 & Libervant remain on track. * Expects to submit AQST-108 (epinephrine) IND by June 2020 and to commence PK trials by end of 2020 * Expecting PDUFA on September 27th 2020 * On May 21st 2020, $AQST Announced plans to advance its strategy to monetize the anticipated royalties associated with Sunovion Pharmaceuticals’ apomorphine sublingual film APL-130277, which received FDA approval to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease. * On June 19th 2020, $AQST Announced that it has submitted an IND application to the FDA for pharmacokinetic (PK) clinical trials of its drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm technologies. The Company intends to initiate its planned PK trials before the year end 2020. * On August 10th 2020, $AQST Announced that the FDA has granted Fast Track designation for the Company’s drug candidate AQST-108.
Upcoming Catalysts * PDUFA is set for Sept 27 2020
Important documents I suggest you read over * 10-K * 10-Q * Corporate Presentation
Price Forecasts/targets * CNN Money sets the median PT at $16 with a high of $33 * Yahoo Finance sets the median PT at $17.83 * NASDAQ sets it as a "strong buy" with median PT of $18.67 with a high of $33 * WallStreetJournal sets the average PT at $17.83 with a high of $33
Final Thoughts/comments * As always, please extend my DD by doing your own on top of everything you've read here. * Now that I have that out of the way, I feel confident about this company and everything they're doing. Especially with the recent financials which showed a 59% growth in sales of their only marketed Product. * For me, I actually mentioned this stock multiple times in the chatroom last week on Monday/Tues where it was close to $6. I bought 100 shares of it & I'll be holding for while :)
Anyways, I hope I've been able to help out with this DD in any way possible :). I'm sorry for the delay, I didn't feel good last week and took some time off, especially since I had a lot to do last week with taking my dad to appts etc. Hope you're all having a great day :) Take care everyone!
submitted by PradoMV96 to EducatedInvesting [link] [comments]


2020.08.06 17:15 ntidwell98 A Thorough DD $CATB (Catabasis Pharmaceuticals)

A Thorough DD $CATB (Catabasis Pharmaceuticals)
What is Catabasis Pharmaceuticals?
  • A community of experts from multiple disciplines who have come together with the common goal of bringing hope and life-changing therapies to patients and their families who suffer from rare diseases.
  • In 2008, CATB recognized that traditional approaches to drug discovery and development may not address the multiple underlying defects causing a disease, and founded Catabasis Pharmaceuticals.
  • CATB's proprietary technology known as SMART (Safely Metabolized And Rationally Targeted) is a Linker drug discovery platform.
    • With this platform, CATB has engineered molecules that simultaneously modulate multiple biological targets within one or more related disease pathways – thus allowing bioactives to reach their targets more efficiently and to have greater efficacy.

Pipeline
https://preview.redd.it/n90pe0h5j3f51.png?width=1643&format=png&auto=webp&s=730f37b93d3f3fa3eb218c232f5e376acec2ff2a
Phase 3 ongoing
Designing Phase 2
Exploring potential in BMD
https://preview.redd.it/etihztfaj3f51.png?width=1643&format=png&auto=webp&s=3eddf279147f08b5ca9456e27ba8fc8d1e6a7f53
  • CAT-5571 is an oral small molecule designed to restore host defense by activating autophagy being developed for the treatment of cystic fibrosis (CF). Autophagy is a mechanism for recycling cellular components and digesting pathogens, which is depressed in CF. People with CF suffer from persistent lung infections with opportunistic pathogens such as P. aeruginosa and B. cenocepacia, causing chronic infections that are difficult to eradicate and ultimately lead to respiratory failure. CAT-5571 has been shown to restore autophagy, reestablish host defense and enhance the clearance of pathogens, including P. aeruginosa and B. cenocepacia, in preclinical models of CF.


Edasalonexent (CAT-1004)
  • Edasalonexent (CAT-1004) is a novel oral investigational drug designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of mutation type.
  • In DMD the lack of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. By inhibiting NF-kB, edasalonexent has the potential to decrease muscle damage and increase the ability of muscle to regenerate.
Edasalonexent is currently being studied in our Phase 3 PolarisDMD trial and the GalaxyDMD open-label extension study. Catabasis is also planning a clinical trial to study edasalonexent in non-ambulatory boys and men ages 10 and older affected by Duchenne.
Clinical results to date
  • In the Phase 2 MoveDMD trial and open-label extension, edasalonexent showed effects on:
    • Muscle function: Edasalonexent preserved muscle function and substantially slowed disease progression through 72 weeks compared to an off-treatment control period. Consistent improvements were observed in the North Star Ambulatory Assessment (NSAA), 4-stair climb, 10-meter walk/run, and time to stand compared to an off-treatment control period.
    • Non-effort-based measures of muscle health: Edasalonexent demonstrated significant reductions in muscle enzymes, including Creatine Kinase (CK), and in C-reactive protein (CRP). In addition, edasalonexent significantly improved the rate of MRI T2 compared to an off-treatment control period, which is consistent with reduction in muscle inflammation and fat content. There was no evidence of adrenal insufficiency for up to 150 weeks, with no clinically significant changes in either cortisol or ACTH.
    • Growth: Boys on edasalonexent grew similarly to boys who do not have DMD. Height increased by an average of 2 inches per year, while weight increased by an average of 3 pounds per year, both in line with typical height and weight increases of similarly aged boys not affected by DMD.
    • Heart health: Elevated resting heart rate is an initial sign of cardiac disease in DMD. The heart rate of boys significantly decreased towards age-normative values through 18 months of edasalonexent treatment.
  • Edasalonexent has also been well-tolerated to date. In more than 100 cumulative years of patient exposure, the majority of treatment-related adverse events have been mild and gastrointestinal in nature.
  • The FDA has granted edasalonexent Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of DMD. The European Commission has granted Orphan Medicinal Product Designation for edasalonexent for the treatment of DMD.
  • Edasalonexent is an investigational drug that is not yet approved in any territory.


NF-kb
  • In Duchenne muscular dystrophy, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal muscle and cardiac disease progression. Learn more about the role of NF-kB in normal muscle, DMD muscle, and muscle where NF-kB is inhibited below.
https://preview.redd.it/zkfaik0gl3f51.png?width=2195&format=png&auto=webp&s=e6109d19c10e7655b77b920b9a2087229204c7ec


PolarisDMD Clinical Trial
  • The Phase 3 PolarisDMD trial is evaluating the safety and efficacy of edasalonexent as a potential novel treatment for Duchenne.
  • The trial enrolled 131 boys ages 4-7 (up to 8th birthday) regardless of mutation who had not been on steroids for at least 6 months.
  • The PolarisDMD trial has clinical trial sites across 8 countries, located in the United States, Canada, United Kingdom, Ireland, Sweden, Germany, Israel, and Australia.
  • The trial is randomized, double-blind and placebo-controlled, with 2 boys receiving edasalonexent for each boy receiving placebo.
  • The primary endpoint for the trial is a change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo, and the trial also includes timed function tests of muscle function as well as additional assessments of growth, cardiac bone health, and quality of life.
  • After 12 months in the study, all boys will have the option to receive edasalonexent in an open-label extension, GalaxyDMD. Top-line results for the PolarisDMD study are expected in Q4 of 2020 and are anticipated to support a New Drug Application (NDA) filing in 2021.

Recent Press Releases

Management/Board of Directors
Jill C. Milne, Ph.D.
  • Co-founder and Chief Executive Officer since June 2008.
  • Prior to co-founding CATB, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline (GSK).
  • From 1998 to 2004, Dr. Milne worked at Pfizer (PFE) Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts.
  • Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.
Joanne M. Donovan, M.D., Ph.D.
  • Chief Medical Officer And Senior Vice President, Clinical Development
  • Since 1989, she has worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology.
  • Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine.
  • From 1998 to July 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex.
  • Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.
Andrew Nichols, Ph.D.
  • Chief Scientific Officer
  • Previously, he served as CATB's Senior Vice President, Research and Development from February 2014 to October 2016.
  • From October, 2013 to February, 2014, Dr. Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a pharmaceutical research company, leading drug discovery and early clinical development programs.
  • Dr. Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck Research Labs from August, 2010 to October, 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August, 2009 to August, 2010.
  • Prior to Merck, Dr. Nichols was Vice President of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline Beecham.
  • He holds an M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of Leeds, England.

Kenneth Bate
  • Chairman since February 2016.
  • From May 2009 until January 2012, Mr. Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company.
  • From January 2007 to April 2009, Mr. Bate was President and Chief Executive Officer of NitroMed, a public pharmaceutical company.
  • From March 2006 until January 2007, Mr. Bate was Chief Operating Officer and Chief Financial Officer of NitroMed.
  • From January 2005 to March 2006, Mr. Bate was employed at JSB-Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies that he co-founded.
  • From 2002 to January 2005, Mr. Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Mr. Bate served as a member of the Board of Directors of Cubist Pharmaceuticals, a public biopharmaceutical company, from June 2003 to January 2015 and was its non-executive Chair from March 2011 to January 2015.
  • Mr. Bate is a director of five other public biopharmaceutical companies, AVEO Pharmaceuticals, Genocea Biosciences, Epizyme Pharmaceuticals, Vanda Pharmaceuticals and Madrigal Pharmaceuticals.
  • During the last five years, Mr. Bate also served as a director of NitroMed and Coley Pharmaceutical Group. He holds an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in chemistry from Williams College.

Financials
  • Current Share Price: $6.55
  • Market Cap: $117.23 million
  • Shares Outstanding: 17.90 million
  • Float: 16.95 million
  • Short Float: 4.91%
  • % held by insiders: 0.57%
  • % held by institutes: 40.87%
  • UBS Group bought 38,266 shares on July 31st, 2020.
  • Vanguard group owns 675,941 shares @ 5.03
  • Federated Investors, Inc. owns 2,122,800 shares @ 5.30

Recent 10-Q/Concerns
  • "The Company has entered into various sales agreements with Cowen and Company LLC, (“Cowen”), pursuant to which the Company could issue and sell shares of common stock, par value of $0.001 per share, under at-the-market offering programs (the “ATM Programs”). The Company pays Cowen 3% of the gross proceeds from any common stock sold through these sales agreements. As of March 31, 2020, the Company has $43.6 million remaining available under its current sales agreement."
  • "During the three months ended March 31, 2020, the Company sold an aggregate of 173,572 shares of common stock pursuant to the ATM Programs, at an average price of $6.29 per share, for net proceeds of $1.1 million after deducting sales commissions and offering expenses."
  • "On January 30, 2020, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc. relating to an underwritten public offering (the “January 2020 Financing”) of 5,290,000 shares of common stock at a price to the public of $5.00 per share, including 690,000 shares issued upon the exercise in full by Oppenheimer & Co. Inc. of its overallotment option. This resulted in gross proceeds of $26.5 million, and net proceeds of $24.6 million."
  • "As of March 31, 2020, the Company had an accumulated deficit of $231.5 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception."
  • "The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company's products. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates."
  • "As of March 31, 2020, the Company had available cash, cash equivalents and short-term investments of $55.1 million. Based on the Company’s current operating plan, the Company believes it has sufficient cash, cash equivalents and short-term investments to fund operations for at least twelve months following the issuance of these condensed consolidated financial statements."
  • "The Company will require substantial additional capital to fund operations. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company's business, results of operations, and financial condition."
  • "Even if we complete the necessary preclinical and clinical studies, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate."
  • "The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved."

Potential Catalysts
  • Top-line results for the PolarisDMD study are expected in Q4 of 2020
  • PolarisDMD anticipated to support a New Drug Application (NDA) filing in 2021.
  • Edasalonexent has a market potential of $4 billion USD
  • Expand clinical experience to all ages within the Duchenne community, including non-ambulatory patients and Becker Muscular Dystrophy.
  • Leverage benefits of inhibiting NF-κB in other potential indications
  • Advance preclinical R&D for CAT-5571 for Drug-Resistant/Sensitive Tuberculosis with recent Gates MRI non-exclusive license.

Upcoming Events
  • Q2 2020 Financial Results due August 10th.
  • 2020 Wedbush PacGrow Virtual Healthcare Conference presentation on August 12th.

Conclusion
Catabasis Pharmaceuticals is a long term hold (6 months-1 year) as the expected news is not until Q4 2020 and following that the NDA filing in 2021. The team behind CATB is very top notch with qualifications all around the board. Snuck into the 10-Q was a statement I bolded, "The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates." If they are anticipating operating losses for the next several years to continue to develop its product candidates, then they fully expect to achieve FDA approval as that is the closest source of revenue to fund these ambitions.
The recent addition of a Chief Commercial Officer (CCO) and their plans for commercialization show the level of confidence in their PolarisDMD Phase 3 clinical trial. Andrew Komjathy, CCO, has an extensive background in biopharmaceutical commercialization having previously worked as Vice President, Commercial Sales for Alkermes Inc.

  • NASDAQ rates CATB a Strong Buy with an average target of $15
  • CNN Business rates CATB a Buy with an average target of $37.50
  • CNBC rates CATB a Strong Buy with an average target of $37.50
  • Yahoo FinanceRates CATB a Strong Buy with an average target of $37.50
  • TipRanks rates CATB a Moderate Buy with an average target of $15
I am personally not rushing into a position quite yet as there is still time to look for the optimal entry before the Q4 results and lack of capital ATM. I believe the company has a good chance at getting the FDA approval for Edasalonexent for Duchenne Muscular Dystrophy (4-7 years) and it seems that CATB might feel the same way by adding Andrew Komjathy as Chief Commercial Officer and some wording in their 10-Q. Also, CATB linking up the with Bill and Melinda Gates Medical Research Institute (Gates MRI) is a huge relationship to initiate. I plan to look for a position roughly 5% of my portfolio size.
As always manage your risk according best to your situation! The information is intended to be unbiased. I invite comments, concerns, and additional information I missed.

EDIT 1: August 17th, 2020
  • Opened position, 25 Shares @ 6.90
submitted by ntidwell98 to EducatedInvesting [link] [comments]


2020.08.03 02:08 DotNetPhenom The Curious Case of BOXL: An Actual DD

BOXL is all the rage in this sub. Everywhere you go you see it, but what is it really? I was curious and decided to dig in. This is my first DD. Inspired by u/vivid_mood
BOXL Company Profile:
Boxlight Corporation is an education technology company that develops, sells and services interactive classroom solutions for the global education market. It designs, produces and distributes interactive technologies including flat panels, projectors, peripherals, and accessories to the education market. It also distributes science, technology, engineering and math products, including its robotics and coding system, three-dimensional (3D) printing solution and portable science lab. All of its products are integrated into its classroom software suite that provides tools for whole-class learning, assessment and collaboration. It also offers professional development and training resources to educators including customized programs, online certifications and in-person courses. It provides services to its clients and customers, including installation, training, consulting and maintenance. Its products are sold in approximately 60 countries and its software is available in over 33 languages.

What Does That Mean?

BOXL has been around since 1985. It originally focused on display technologies for business, government, and education applications, before pivoting and focusing almost exclusively on education after 24 years in 2009. It does this through three companies:
  1. Qwizdom - A company founded 35 years ago that makes a software that utilizes physical "clickers" or a mobile app to allow you to ask a multiple choice question in a powerpoint and see the results afterward. Its basically a live polling feature for powerpoint.
  2. EOS Education- This company was started as a spin-off in 2015 and acquired in 2018 by Boxlight. The company website says:
As co-founders of Immedia and leaders of the K-12 division, ImmediaEDU, we have worked exclusively with more than 300 schools and thousands of teachers providing technology hardware, consulting, installation and professional development services.
So either the co-founders worked with the 300 schools when they were Immedia, or combined between the two of them they have worked with 300 schools. It's a bit of word salad, and this is an education company, but I'm digressing.
Further reading shows its a wife and husband team Aleksandra Leis and Daniel Leis, of which Daniel Leis was a co-founder of Immedia, a company wherein he no longer appears on the site and wherein his spinoff company is not listed as a partner. The site further clarifies:
Prior to EOS, he was one of the founders of Immedia Integrated Technologies, serving on the Management Team of the company and as President of Immedia Education, the specialized K-12 division of the company.
So perhaps he was a founding member and not an actual founder. Who knows. Either way he isn't the CEO of EOS Education, which is strange because he has the most C-Level experience between him(he had his own company and worked for P&G C-Level) and his wife(who is the actual CEO) but perhaps this is because his wife has a higher stake in the company in order to allow them access to minority set aside contracts. A little shady? Maybe :shrugs:
Who is his wife?
Aleksandra Leis, with her C-Level experience coming from being a CEO of a marketing research company in Eastern Europe, while incidentally Mr. Leis had a market research consulting firm based in Eastern Europe that was acquired by Proctor & Gamble? Same company? Who knows. She was an associate professor of Social Sciences before that.
The company offers professional development services to teachers K-12, which teaches them how to use G-Suite, Office 365, Boxlight products, and competing products(Google Classroom, Canvas, Edmodo, Blackboard, Promethean, Smart). Some other products include videos of other classrooms that can help teachers come up with new strategies/methods, district-specific lesson libraries, videos that teachers can add to their lessons to improve student interaction, classroom websites(similar to blackboard), district-level mobile apps, and classroom monitoring solutions for administrators that facilitates micromanagement of every classroom.
  1. Modern Robotics- This company facilitates the exploration of robotics in the classroom utilizing both proprietary and open source equipment sold on the website.
Honestly, of all the companies they own EOS's Aleksandra and Daniel Leis seem to be the ones who are going to be in charge of leading the company to some sort of profitability. The other two companies well idk, what do you think? And what about parent company Boxlight? Do you think their classroom display technology will be valuable in a virtual classroom?

Key Financials

Profitability
Profit Margin -19.98%
Operating Margin (ttm)-24.86%
Revenue (ttm)33.76M
Quarterly Revenue Growth (yoy)14.60%
Gross Profit (ttm)8.94M
EBITDA -7.51M
Balance Sheet
Total Cash (mrq)612.94k (o.O)
Total Debt (mrq)6.78M
Operating Cash Flow (ttm)-5.72M
Levered Free Cash Flow (ttm)-7.2M
Shareholder Information
Shares Outstanding 31.86M
Float 12.66M
Shares Short (Jul 15, 2020) 1.06M
Short % of Float (Jul 15, 2020) 4.02%
% Held by Institutions 5.02%

The Offfering

The company has had two offerings in the past two months underwritten by Maxim Group. This is where it gets a little confusing for me.
The first offering was for 13.3333M shares @ $0.75 with a 2M share option worth $10M total.
The second was for 15M shares @ $2.00 with an option for 2.25M worth $30M total but the total shares outstanding is 31.86M and the float is 12.66M.
Technically, wouldnt both of these transactions equal almost 100% of the shares outstanding because Maxim Group has exercised their options both times?
Also, the short percentage of 4.02% was as of 7/15. Finviz shows shares outstanding 12.49M with a float of 11.77M a much smaller insider ownership percentage. That would mean make the short percentage almost 10%, and would mean it could've occured after the spike on 7/14. Recent activity could simply be short action, and the stock could actually be due for intense downward pressure, compounded by the lower offering.

My Other Questions

Does Maxim group count as an insider or do they make up the float? Yahoo finance doesnt list them.
What's the actual float?
Whats the actual ratio of insider shares to public shares?
Who's REALLY invested in this?
What are the odds the 5% institutional holdings are almost all short? (short 4.02%)
Why is the company not profitable? What percentage of the expenses do the other companies make up?
How will the potential COVID related revenue increase offset that?
Welp, that's it for me guys. Let me know what you think in the comments. How was this DD? Is this company a pass or gas?
submitted by DotNetPhenom to pennystocks [link] [comments]


2020.07.30 09:00 Cicero1982 Your Pre Market Brief for 07/30/2020

Pre Market Brief for Thursday July 30th 2020

You can subscribe to the daily 4:00 AM Pre Market Brief on The Twitter Link Here . Alerts in the tweets will direct you to the daily 4:00 AM Pre Market Brief in this sub.
Morning Research and Trading Prep Tool Kit
The Ultimate Quick Resource For the Amateur Trader.
Published 3:00 AM EST / Updated as of 4:35 AM EST
-----------------------------------------------
Stock Futures:
Wednesday 07/29/2020 News and Markets Recap:
Thursday July 30th 2020 Economic Calendar (All times are Eastern)
JOBLESS CLAIMS AND GDP TODAY!
News Heading into Thursday July 30th 2020
NOTE: PLEASE DO NOT YOLO THE VARIOUS TICKERS WITHOUT DOING RESEARCH. THE TIME STAMPS ON THE FOLLOWING ARTICLES MAY BE LATER THAN OTHERS ON THE WEB. THE CREATOR OF THIS THREAD COMPILED THE FOLLOWING IN A QUICK MANNER AND DOES NOT ATTEST TO THE VERACITY OF THE INFORMATION BELOW. YOU ARE RESPONSIBLE FOR VETTING YOUR OWN SOURCES AND DOING YOUR OWN DD.

Note: Seeking A url's and Reddit do not get along.
Upcoming Earnings:
COVID-19 Stats and News:
Macro Considerations:
Most Recent SEC Filings
Other
-----------------------------------------------
Morning Research and Trading Prep Tool Kit
Other Useful Resources:
The Ultimate Quick Resource For the Amateur Trader.
Subscribe to This Brief and the daily 4:00 AM Pre Market Brief on The Twitter Link Here . Alerts in the tweets will direct you to the daily brief in this sub
It is up to you to judge the accuracy and veracity of these headlines before trading.
submitted by Cicero1982 to pennystocks [link] [comments]


2020.07.29 23:39 PradoMV96 A thorough DD on $ALDX (Aldeyra Therapeutics)

What is Aldeyra Therapeutics? * Aldeyra is dedicated to improving the lives of patients suffering from immune-mediated ocular and systemic diseases. We are advancing a broad pipeline of product candidates diversified by chemical composition, mechanism of action, and clinical indication * They are a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases * Their Pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments. By inventing, developing and commercializing these next-generation therapies, they have one goal: to help patients lead healthier lives.
What are their Pipeline products? * Link to their Pieplines * As I have mentioned earlier, they are working on product candidates to tacvkle to problem areas: * Ocular Diseases * Systematic Disease
What are their delivery mechanisms? * RASP (reactive aldehyde species) * CHP (Chaperome Inhibition) * DHFR (Dihydrofolate reductase inhibition)
What are RASP (reactive aldehyde species)? * RASP are reactive molecules that covalently bind to cellular biomolecules, disrupting their function and activating pro-inflammatory mediators. * RASP are formed by a variety of processes, including lipid peroxidation, alcohol oxidation, polyamine and glucose metabolism. * Mechanism of RASP: * RASP effect inflammation signaling via covalent binding to proteins, including receptors and enzymes. * RASP-protein adducts directly influence the function of proteins, leading to activation of intracellular inflammatory factors, including NF-kB, an important mediator in the inflammatory response. * In addition, RASP-protein adducts bind to Scavenger Receptor A, which also initiates pro-inflammatory signaling and leads to the formation of antibodies against the adducted protein, at least in part explaining the presence of host-directed antibodies in autoimmune diseases such as rheumatoid arthritis
** What is CHP (Chaperome Inhibition)?** * Chaperomes are proteins that interact with other proteins to facilitate folding and other processes required for proper function. * The chaperomes heat shock protein 90 (HSP90) and heat shock cognate protein 70 (HSC70) are involved in the processing of proteins that are critical for physiologic cellular function and replication. * A network of molecular chaperones is known as the chaperome. * Inhibition of the chaperome leads to diminished cellular replication, which is unregulated in cancer and in many immune-mediated diseases
What is DHFR (Dihydrofolate reductase) * Dihydrofolate reductase (DHFR) is an enzyme involved in cellular replication and activation * Methotrexate, the active component of ADX-2191, is a DHFR inhibitor, which has been used to treat cancer and autoimmune disease * The anti-proliferative and anti-inflammatory properties of DHFR inhibition are well described.
Ocular Diseases: * Reproxalap: * It is meant to treat Dry Eye Disease * Currently in the middle of Phase 3 CLinical Trials * uses the RASP mechanism * Reproxalap: * Will be used to treat Allergic Conjuctivitis * Currently in the middle of Phase 3 clinical trials * uses the RASP mechanism * ADX-2191: * will be used to treat Proliferative Vitreoretinopathy * currently in Phase 3 of clinical trials * uses the DHFR mechanism * ADX-2191: * will be used to treat Intraocular Lymphoma * Currently in Phase 2 of clinical trials * uses the DHFR mechanism * ADX-103/10X: * Will be used to treat Retinal Disease * Currently in Pre-Clinical Trial Phase * uses the RASP mechanism
Ocular Diseases $ALDX plans to treat: * Dry Eye Disease * Allergic Conjunctivitis * Proliferative Vitreoretinopathy * Link
Systemic Diseases $ALDX plans to treat * Ovarian Cancer * Link
What is Dry Eye Disease & how do they plan to treat it? * Link * There are approximately 34 million dry eye disease patients in the United States * Reproxalab is their novel small molecule drug candidate for dry eye disease * By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease * They believe that reproxalap may have a commercially differentiated product profile versus currently approved drugs for each indication, having shown the potential for early and broad activity in dry eye disease. * Additionally, reproxalap, if approved, has added the potential of being the only product that may be able to effectively treat dry eye disease, uniquely addressing the needs of the large underserved population that suffers from this disease * In a Phase 2b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.
What is Allergic Conjunctivitis & how do they plan to treat it? * Link * The symptoms of allergic conjunctivitis is ocular itching and tearing which are chronic, painful and persistent, affecting the quality of life and leading to a loss of work that can create a substantial economic burden on patients and their families * allergic conjunctivitis is one of the most common diseases treated by ophthalmologists. In many cases, physicians and patients say currently available therapy as inadequate. * Approximately 100 million patients in the United States have allergic conjunctivitis, and they estimate that up to 30 million of these patients either don’t respond adequately to, or are dissatisfied with, topical antihistamines, the current standard of care. * They plan to use Reproxalab with RASP mechanism to treat allergic Conjunctivitis * if approved, it has the added potential of being the only product that may be able to effectively treat allergic conjunctivitis, uniquely addressing the needs of the large underserved population that suffers from this disease.
What is Proliferative Vitreoretinopathy & how do they plan to treat it? * Link * Proliferative vitreoretinopathy (PVR) is a rare inflammatory disorder of the retina that leads to severe retinal scarring and blindness and is the leading cause of failure of retinal reattachment surgery * Over 50% of PVR cases result in severe uncorrectable vision loss (visual acuity of 20/320 or worse), and 76% of PVR patients suffer from at least moderate uncorrectable vision loss * inhibiting cell growth and thereby diminishing scar formation, ADX-2191 has the potential to be the first FDA-approved drug for prevention of PVR. * In April 2018, ADX-2191 received orphan drug designation from the FDA for the prevention of PVR.
What is Ovarian Cancer & how do they plan to treat it? * Link * Ovarian cancer is often fatal and is generally diagnosed only after significant tumor progression. * Five-year survival is less than 50%. In the United States, over 225,000 women have ovarian cancer * Aldeyra’s chaperome inhibitors, in combination with DNA-damaging agents, may have utility in the treatment of certain cancers. * The chaperome inhibitor system is required for DNA repair, and chaperome inhibition in the setting of DNA damage could lead to cancer cell death
Recent Financials & business highlights * For the quarter ended March 31, 2020, Aldeyra reported a net loss of $9.9 million, compared with a net loss of $15.6 million for the quarter ended March 31, 2019 * loss per share was $0.34 for the quarter ended March 31, 2020, compared with $0.58 for the same period in 2019 * Cash, cash equivalents, and marketable securities were $61.4 million as of March 31, 2020. * Cash Runway Extended into 2022 * ADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in 2020 * Type C Meeting Scheduled with FDA to Discuss Remaining NDA Requirements for Reproxalap in Dry Eye Disease * Results from Phase 3 INVIGORATE Trial of Reproxalap in Allergic Conjunctivitis Expected in First Half of 2021 * Link
Risks/Negatives of the Business * As found on their recent 10-K/10-Q: * "Our business is dependent in large part on the success of a single product candidate, reproxalap, for which we are researching multiple indications. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, reproxalap." * "We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts." * "Our business has been and will continue to be adversely affected by the COVID-19 pandemic." * "The results of preclinical studies and earlier clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials, including reproxalap, may not have favorable results in later clinical trials, if any, or receive regulatory approval." * "Because some of our product candidates are, to our knowledge, new chemical entities, it is difficult to predict the time and cost of development and our ability to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization." * "Final marketing approval for reproxalap or our other product candidates by the FDA or other regulatory authorities may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues." * "Even if we receive regulatory approval for reproxalap or any other product candidate, we still may not be able to successfully commercialize, and the revenue that we generate from its sales, if any, could be limited." * "If the market opportunities for reproxalap and our product candidates are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer" * "If we fail to develop and commercialize other product candidates, we may be unable to grow our business." * "Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products." * "We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products." * "We may not be successful in establishing and maintaining development, commercial, or other strategic partnerships, which could adversely affect our ability to develop and commercialize product candidates." * "If our competitors develop treatments for the target indications of our product candidates that are approved more quickly than ours, marketed more successfully, or demonstrated to be safer or more effective than our product candidates, our commercial opportunity will be reduced or eliminated." * "We are highly dependent on the services of our senior management team and certain key consultants." * Links to the SEC filings regarding the risks I've mentioned plus more and in more detail as well: * 10-Q * 10-K
Events to positively impact Q2-Q4 of 2020 * On December 23rd 2019, $ALDX Announced positive top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease. * Consistent with clinical experience in over 1,100 patients, no adverse findings on safety assessments were observed, and reproxalap was well-tolerated. The most common reported adverse event in reproxalap-treated patients was transient and mild instillation site irritation * On January 21st 2020, $ALDX Announced enrollment of the first patient into the Phase 3 INVIGORATE Trial of topical ocular reproxalap in patients with allergic conjunctivitis. * The INVIGORATE Trial, which will enroll approximately 120 patients, is a randomized, double-masked, crossover vehicle-controlled Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared with vehicle using an allergen chamber. * On January 28th 2020, $ALDX Announced the appointment of Paul Karpecki, O.D., FAAO, to the company’s Anterior Segment Scientific Advisory Board. * Paul is a nationally recognized leader in the field of optometry * His more than 20 years of expertise is expected to be extremely valuable as they continue to advance reproxalap and their novel RASP inhibitor platform toward NDA submission in dry eye disease and allergic conjunctivitis. * On March 12th 2020, $ALDX Announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. * In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M.D., as Senior Vice President of Clinical Development. * On March 24th 2020, $ALDX Announced that they will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection. * ADX-629 and reproxalap are structurally related to chloroquine and hydroxychloroquine, drugs currently in clinical testing for the treatment of COVID-19 infection. * On April 14th 2020, $ALDX Announced positive top-line Phase 1 clinical trial results for ADX-629, a first-in-class orally available reactive aldehyde species (RASP) inhibitor in development for the treatment of systemic immune-mediated diseases. * On May 20th 2020, $ALDX Announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibitor in development for COVID-19 and other inflammatory diseases. * ADX-1612, which has been clinically tested in more than 1,600 subjects for the potential treatment of cancer, is an inhibitor of chaperone protein HSP90, a target widely implicated in viral disease * Aldeyra announced that ADX-1612 has demonstrated nanomolar potency similar to or greater than that of remdesivir in an in vitro model. Complementary to the nucleic acid inhibition mechanism of action of remdesivir and related antiviral compounds, ADX-1612 potentially leads to the inhibition of proteins associated with viral replication and infection, and thereby may enhance the activity of other antiviral drugs for the treatment of COVID-19. * Pending FDA feedback, an Investigational New Drug (IND) submission for ADX-1612 is expected in the third quarter of 2020. * On June 4th 2020, $ALDX Announced that, based on preliminary written comments and meeting discussion, agreement has been reached with the FDA for the use of RASP as an objective sign for the treatment of dry eye disease. * On June 15th 2020, $ALDX Announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. * ADX-2191 has the potential to be the first pharmacological prophylaxis to prevent retinal detachment associated with PVR. * On July 7th 2020, $ALDX Announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease. * Based on FDA meeting minutes, Aldeyra intends to initiate two clinical trials to assess the activity of reproxalap in reducing tear levels of RASP, pro-inflammatory mediators recently accepted by the FDA as an objective sign of dry eye disease. * On July 14th 2020, $ALDX Announced block sales of an aggregate of 4,580,361 shares of common stock to Perceptive Advisors, LLC and Avidity Partners Management LP. * The shares were sold for a price of $4.25 per share * Aggregate gross proceeds, before deducting commissions, were approximately $19.5 million * Aldeyra anticipates using the net proceeds from the sales for the continued development of the company’s lead compound reproxalap and other product candidates, as well as for debt maintenance, working capital, and other general corporate purposes * marketable securities are sufficient to fund operations through the end of 2022
Presentations & important files I suggest you read * Corporate Presentation * 10-K * 10-Q
Price Target/Forecasts * CNN MONEY sets the average PT at $30 with a high of $34 * NASDAQ sets it as a strong buy with an average PT of $26.75 with a high of $34 * WallStreetJournal sets the average PT at $27.20 with a high of $34 * Yahoo Finance sets the 1yr price estimate at $27.33 with a high of $34 * MarketBeat sets the average PT at $26.50 with a high of $33 * TipRanks sets the PT at $26.75
Upcoming/future Catalysts * 2nd Quarter earnings is in August * ADX-629 cytokine release syndrome Phase 2 clinical trial initiation in COVID-19 associated respiratory compromise is in Q3 2020 * Top-line results from the first of the RASP trials are expected by the end of 2020 * the Coronavirus Treatment Acceleration Program (CTAP), is expected to begin in the third quarter of 2020. * COVID-19 IND submission Q3 2020 * COVID-19 clinical trial initiation Q4 2020 * A Phase 2a clinical trial of ADX-629 is expected to begin in the second half of 2020 * A Phase 2a allergen-challenge clinical trial of ADX-629 is expected to begin in the second half of 2020. * Phase 3 trials of Reproxalab in Allergic Conjunctivitis is expected first half of 2021
Final Thoughts/Comments * As always Everyone, please extend my DD by adding onto it by doing your own research as well, Especially by taking a look at the corporate Presentation I've attached & the SEC Filings I've attached as well :) * Now with that out of the way, for me, I personally strongly believe in what this company has to offer, especially since they are Targeting large markets, not only that, but large & underserved markets. * Plus the realization that one of their pipeline products has is structurally related to chloroquine and hydroxychloroquine, which are drugs currently in clinical testing for the treatment of COVID-19. * Because they already have a product that is molecularly & structurally related to the main COVID-19 treatments, it puts them ahead of the game in terms of joining the race to develop COVID-19 vaccine. * Because of their pipeline Catalysts coming up, business updates coming up in the 2nd quarter earning, COVID-19 Catalysts coming up and the fact that they have enough money to fund them through 2022, I genuinely see their stock price moving positively towards that PT. * I want it to be clear, for the most part, this is a LONG HOLD stock I plan to hold them through the next year
Anyways guys! Sorry for the delay in posting this one. This DD has a lot of info I did my best to cover & summarize for you guys :) Hope you all have a wonderful day today & week. Take care everyone! I'll hopefully be posting another DD by tonight, if not tomorrow morning. Take care everyone :)
submitted by PradoMV96 to EducatedInvesting [link] [comments]


2020.07.27 11:56 27JJuldacket Bike Riders Da-ting Si-te

Bike Riders Da-ting Si-te
Check the Profiles for Free >>>>>>>>>> 🔴►🔴► Dating
Righter Dating Site Rondevo Dating Site Russian Women Dating Site Samoan Dating Site Sample Profiles for Dating Sites Search Dating Sites by Email Free Search Dating Sites by Name Separated Dating Site Serious Dating Sites for Marriage Sex Dating Sites for Over 50s Sex Only Dating Sites Shine Love on Me Dating Site Single Mother Dating Site Site Dating Romania Slavic Dating Sites Social Anxiety Dating Site Spokane Dating Sites Std Positive Dating Sites Submissive Dating Site Sugar Daddy Com Dating Site Switzerland Dating Sites Tagged Dating Site Sign Up Tagline for Dating Site Taglines for Dating Sites Taiwan Dating Site Tampa Dating Sites Tender Com Dating Site Text Dating Sites Tg Dating Site The Cage Dating Site The Inner Circle Dating Site Tinder Dating Site Login Tn Tnpaym Com Dating Site Top 10 Best Dating Site Top 10 Dating Sites 2019 Top 10 Dating Sites in Usa Top Dating Site 2018 Top Free Online Dating Sites Top Gay Dating Sites Top Sex Dating Sites Totally Free Chinese Dating Sites Totally Free Online Dating Sites Uk Transsexual Dating Sites Apps Trinidad Dating Site True Dating Site Tulsa Dating Sites Unicorn Hunters Dating Site Unlimdate Dating Site Untrue Dating Site Valentine Com Dating Site Verified Millionaire Dating Sites Vermont Dating Sites Want a Baby Dating Site Wantmatures Dating Site What Are the Dating Sites What is the Best Dating Site for 50 Year Olds What is the Best International Dating Site What's Your Price Dating Site Whats a Good Dating Site Where Are All the Poly Dating Sites Which Dating Sites Are Free White Dating Site White Only Dating Site Why is My Boyfriend Still on Online Dating Sites Why Would a Married Man Join a Dating Site Wild Dating Site Witch Dating Sites Www Dating Site Www Pof Dating Site X Rated Dating Sites Yesnomayb Dating Site You Love Dating Site Zoosk Com Dating Site 100 Free Dating Site in Nigeria 100 Free Dating Sites for People With Herpes 100 Free Dating Sites No Hidden Costs 100 Free German Dating Sites in English 100 Free Local Dating Sites in Usa 100 Free Online Arab Dating Sites 100 Free Online Dating Site in Thailand 100 Free Online Military Dating Sites 100 Percent Free Adult Dating Sites 100 Percent Free Muslim Dating Sites 101 Fusion Dating Site 12 Year Old Dating Sites for Free 1st Online Dating Site 40 Plus Dating Sites in India 4pple Dating Site 5 Best Married Dating Sites A Dating Site for 11 Year Olds A Dating Site for Kids A Free Dating Site in Usa Abf Dating Sites Abuja Nigeria Dating Site Ace Dating Site Active Duty Dating Site Adore Dating Site Adult Dating Site Malaysia Afghanistan Free Dating Sites African American Online Dating Sites Afrikaanse Dating Sites Age Group Dating Sites Aimer World Dating Site Algoa Fm Dating Site Alice Springs Dating Site All 100 Free Dating Sites All Free Dating Site Com All Social Dating Sites Alliance Dating Site Alligator Dating Site American Dating Sites Usa American Military Dating Sites Amoory Free Dating Site Amp Dating Site Anastasia Russian Dating Site Angola Dating Site Any Legit Dating Sites Apostolic Dating Sites Free Are Asian Dating Sites Legitimate Are Dating Sites Considered Social Media Are Online Dating Sites Any Good Are Paid Dating Sites Better Are There Any Good Asian Dating Sites Are There Any Legit Russian Dating Sites Are There Any Totally Free Dating Sites Armenian Online Dating Sites Asd Dating Sites Asexual Dating Sites Usa Asia Best Dating Site Asian Dating Review Sites Asian Dating Sites Gold Coast Asian Kisses Dating Site Asian Married Dating Sites Asian Women Dating Black Men Dating Sites Aspergers Autism Dating Sites Attractive Usernames for Dating Sites Australia's No 1 Dating Site Autism Dating Site Reviews Back Porch Dating Site Bangalore Local Dating Site Batam Dating Site Beard Lovers Dating Site Beast Dating Sites Beautiful Dating Site Beautiful People Dating Site Review Best Asian Dating Site 2018 Best Bisexual Dating Sites Best Casual Dating Sites 2015 Best Casual Dating Sites Australia Best Christian Dating Site in Europe Best Clean Dating Sites Best Completely Free Dating Sites 2017 Best Dating Site for 25 Year Old Male Best Dating Site for 40 Year Old Woman Best Dating Site for Females Best Dating Site Names Best Dating Site to Meet Filipinas Best Dating Site Without Registration Best Dating Sites 2013 Best Dating Sites and Apps 2019 Best Dating Sites for 24 Year Olds Best Dating Sites for 30 Best Dating Sites for 30 Year Old Woman Best Dating Sites for Black Singles Uk Best Dating Sites for Married Best Dating Sites for Mixed Race Best Dating Sites for Plus Size Best Dating Sites for Stoners Best Dating Sites for Travelers Best Dating Sites for Women 2019 Best Dating Sites in Kolkata Best Dating Sites in Morocco Best Dating Sites in Toronto Area Best Dating Sites in Vietnam Best Dating Sites London Best Dating Sites Ontario Canada Best Dating Sites Profiles Best Dating Sites Right Now Best Dating Sites Uk for Over 50 Best Free Casual Dating Sites Uk Best Free Dating Site on Android Best Free Dating Site Over 50 Best Free Dating Site Yahoo Answers Best Free Dating Sites for 40 Plus Best Free Dating Sites in Scotland Best Free Dating Sites Vancouver Best Free Dating Sites Without Subscription Best Free Local Dating Sites Best Free Teen Dating Sites Best Free Wordpress Theme for Dating Site Best Gay Lesbian Dating Sites Best Germany Free Dating Site Best Ghana Dating Site Best Girl Dating Sites Best Keywords for Dating Sites Best Latino Online Dating Sites Best Low Cost Dating Sites Best Mexico Dating Site Best Military Dating Sites Free Best Older Woman Younger Man Dating Sites Best Online Dating Site for Early 20s Best Online Dating Sites for Over 45 Best Online Dating Sites in Europe Best Online Dating Sites in London Best Online Dating Sites in New Zealand Best Online Dating Sites Northern Ireland Best Online Dating Sites Sydney Best Otaku Dating Site Best Photo Dating Site Best Popular Free Dating Sites Best Premium Dating Site Best Premium Dating Sites Best Quality Dating Site Best Real Indian Dating Site Best Senior Dating Sites Canada Best Senior Dating Sites Reviews Best Serious Dating Sites 2018 Best Single Dating Sites Free Best Site for Over 50 Dating Best Sri Lankan Dating Site Best Totally Free Asian Dating Sites Best Vegan Dating Site Big and Beautiful Dating Site Reviews Bike Riders Dating Site Billionaire Match Dating Site Black Bbw Dating Sites Black Dating Sites Australia Black Dating Sites in Dallas Tx Black Men White Women Dating Site Blackcrush Dating Site Bloemfontein Dating Site Boomer Dating Site Bots on Dating Sites Boyfriend Has Profile on Dating Site Brandon Dating Site Bronx Dating Sites Bumble Dating Sites Tinder Burundi Dating Sites Can You Find Love on a Dating Site Cat Person Dating Site Catchy Bios for Dating Sites Cdff Christian Dating Site Central American Dating Sites Central Florida Dating Site Central Florida Dating Sites Cheating Dating Sites Australia Check Dating Sites by Email Check if Your Partner is on Dating Sites Check to See if Someone is on a Dating Site Cheese Dating Site Chemistry Com Dating Site Chicago Area Dating Sites Chihuahua Dating Site Chill Dating Site China Dating Site 100 Free China Free Online Dating Site Christian Community Dating Site Christian Courtship Dating Sites Christian Dating Site in Ghana Christian Dating Site Pretoria Christian Dating Site Usernames Christian Dating Sites Namibia Cincinnati Dating Sites Coffee and Beans Dating Site College Degree Dating Site Comic Fan Dating Site Completely Free Dating Sites No Credit Card Completely Free Online Gay Dating Sites Computer Geek Dating Site Conspiracy Theory Dating Site Consumer Reports Best Dating Sites Consumer Reports Dating Sites Cool Fm Dating Site Cost Comparison of Dating Sites Cougar Dating Sites Ireland Countryside Dating Sites Free Cousin Dating Site Create Your Own Dating Site Free Creating a Username for Dating Site Cumbria Dating Site Cute Girl Usernames for Dating Sites Dark Obsession Dating Site Dateolicious Dating Site Dating Adults Site Dating Adventist Site Dating Black Girl Site Dating Disability Sites Dating Locator 81 Site Unsub Dating Networking Sites Free Dating Site Ad Dating Site Cz Dating Site Description Examples Dating Site Doctors Uk Dating Site Drawings Dating Site Email Lookup Dating Site Email Search Free Dating Site Fees Dating Site for Black Man and White Woman Dating Site for Celibate Singles Dating Site for Construction Workers Dating Site for Erectile Dysfunction Dating Site for Girlfriend Dating Site for Haters Dating Site for Homeless Dating Site for Korean Guys Dating Site for Law Enforcement Professionals Dating Site for Married Australia Dating Site for Medical Students Dating Site for Night Shift Workers Dating Site for Normal People Dating Site for Phish Fans Dating Site for Pirates Dating Site for Psychopaths Dating Site for Spanish Speakers Dating Site for Tall Singles Dating Site for Uk Fans Dating Site Indonesia Dating Site Just Friends Dating Site Lausanne Dating Site Member Search Dating Site on Snapchat Dating Site Planet Dating Site Reviews Ashley Madison Dating Site Sayings Dating Site Scammer Pictures Dating Site Slang Dating Site Statistics Dating Site Stocks Dating Site Support Dating Site That Got Hacked Dating Site That Looks Like Facebook Dating Site That Starts With L Dating Site to Meet White Ladies Dating Site Topics Dating Site Transwomen Dating Site Twintigers Dating Site Username Examples Dating Site Usernames for Guys Dating Site Where You Have to Be Attractive Dating Site Wordpress Template Dating Sites 2006 Dating Sites 40 50 Dating Sites Cambridge Ontario Dating Sites Central Illinois Dating Sites F Dating Sites for 13 15 Dating Sites for Asian Professionals Dating Sites for Busy Professionals Dating Sites for Chubby Girls Dating Sites for Deaf Singles Dating Sites for Female Bodybuilders Dating Sites for Full Figured Women Dating Sites for International Relationships Dating Sites for Lonely People Dating Sites for Older Man Younger Woman Dating Sites for Over 50 Year Olds Dating Sites for People Over 40 Dating Sites for Sex Offenders Dating Sites for Women Over 40 Dating Sites for Women With Children Dating Sites Free Cupid Dating Sites Free Look Dating Sites Free to Send and Receive Messages Dating Sites Gone Wrong Dating Sites Grand Junction Co Dating Sites Greenville Nc Dating Sites in Bangalore Dating Sites in Beirut Lebanon Dating Sites in Belgaum Dating Sites in Chesterfield Dating Sites in Delhi Dating Sites in Egypt Dating Sites in Fiji Islands Dating Sites in Moscow Idaho Dating Sites in Nigeria Nairaland Dating Sites in San Diego Ca Dating Sites in South Jersey Dating Sites in Toronto Canada Dating Sites in Visakhapatnam Dating Sites in Washington State Dating Sites Killeen Tx Dating Sites Like Match Com Dating Sites Montreal Free Dating Sites Northern Virginia Dating Sites Norway Sweden Dating Sites Overview Dating Sites Playa Del Carmen Dating Sites Portland Oregon Dating Sites Profile Tips Dating Sites Santa Cruz Ca Dating Sites Similar to Okcupid Dating Sites Sussex Dating Sites That Cost No Money Dating Sites That Do Background Checks Dating Sites That Don T Charge Dating Sites That Pay You Dating Sites That Work Reddit Dating Sites to Meet Military Men Dating Sites to Start a Family Dating Apps


https://preview.redd.it/puu79vabhdd51.jpg?width=275&format=pjpg&auto=webp&s=8a749d8652052dedb066cebd1f5eb076df995865
submitted by 27JJuldacket to u/27JJuldacket [link] [comments]


2020.07.27 11:54 27JJuldacket Play No Games Da-ting Si-te

Play No Games Da-ting Si-te
Check the Profiles for Free >>>>>>>>>> 🔴►🔴► Dating
Depression Dating Site Down Dating Site Drug User Dating Site Dubai Dating Site Elitesingles Christian Dating Sites Exclusive Dating Sites Executive Dating Sites Exotic Monkey Dating Site Fake Dating Sites Firefighter Dating Site Fish Com Dating Site Fish in the Sea Dating Site Flirt Dating Site Review Flurv Dating Site Sign Up Free Dating Site in Japan Free Dating Site on Phone Free Dating Sites Dayton Ohio Free Dating Sites for Country Folks Free Dating Sites for Hiv Positive People Free Dating Sites in Chicago Free Dating Sites in Houston Free Dating Sites in Maine Free Dating Sites in Michigan Free Dating Sites No Charge Free Hiv Dating Sites Hiv Positive People Free Hiv Positive Dating Sites Free Nude Dating Sites Free Older Women Dating Sites Free Phone Dating Sites Free Poly Dating Sites Free Safe Dating Sites Free Senior Dating Sites Reviews Free Swinger Dating Sites Free Texting Dating Sites Free Threesome Dating Sites Free Xxx Dating Sites Friends Dating Site Galactic Dating Site Gay Asian Dating Site Gay Dating Sites for Serious Relationships Gay Dating Sites in Usa Gaycupid Dating Site Georgian Dating Sites Gospel Lovers Dating Site Gypsy Dating Site Harley Dating Site Headline Examples for Dating Sites Hermaphrodite Dating Site Hiv Online Dating Sites Hotwife Dating Site How Many Dating Sites Are There How to Bypass Paid Dating Sites How to Start a Conversation on a Dating Site How to Write a Profile for a Dating Site Hush Love Dating Site Review Indianapolis Dating Sites Intellectual Dating Sites International Cupid Dating Site Is My Husband on Dating Sites Is Pof a Good Dating Site Is Tinder a Good Dating Site Is Tumblr a Dating Site Is Zoosk a Free Dating Site Japanese Dating Site in Usa Kamimachi Site Dating Story Korean Dating Site for American Latin American Cupid Dating Site Lavalife Dating Site Usa Lesbian Dating Sites Near Me Long Distance Dating Sites Looking for Free Dating Sites Los Angeles Dating Sites Loving Feel Dating Site Male Dating Sites Match Free Dating Site Mate Com Dating Site Mature Gay Dating Sites Middle East Dating Sites Milfaholic Dating Site Mobile Dating Site Most Popular Dating Sites 2019 Nasty 42 Year Olds Dating Site New Dating Sites 2019 New Free Dating Site in Usa New Online Dating Site New Zealand Dating Sites No Credit Card Needed Dating Sites Oklahoma Dating Sites Older for Younger Dating Sites Online Gay Dating Site Crossword Clue Otaku Dating Site Over Fifty Dating Site Plenty of Fish in the Sea Dating Site Plentyoffish Com Dating Site Plural Marriage Dating Site Pof Com Dating Site Pof Dating Site Sign in Poly Dating Sites Free Positive Herpes Dating Sites Positive Singles Free Dating Hiv Personals Site Pregnant Women Dating Site Quit the Games Dating Site Real Mature Singles Dating Site Real Sex Dating Sites Religious Dating Sites Reputable Dating Sites Rich Chinese Dating Site Russian and Ukraine Dating Sites Sacramento Dating Sites San Antonio Free Dating Sites Satanic Dating Site Seekingarrangement Dating Site Seventh Day Adventist Dating Site Sex Offender Dating Sites Silver Dating Site Reviews Smash Tonight Dating Site Sp Dating Site Spanking Dating Sites Std Community Dating Site Std Dating Site Reviews Submissive Dating Sites Successful Dating Sites Swipe Dating Site Tagged Com Dating Site Tagged Dating Site Login Teen Lesbian Dating Sites Tender Dating Sites Top Dating Sites 2019 Top Dating Sites for Seniors Top Dating Sites in America Totally Free Dating Sites for Seniors Totally Free Dating Sites Like Plenty of Fish Turkish Dating Sites Twin Dating Site Ukrainian Charm Dating Site Victoria Dating Site Video Dating Site Video Dating Sites Wealthy Men Dating Site West Indian Dating Sites What is Pof Dating Site Why Do I Get Spam Emails From Dating Sites Why Does My Husband Get Texts From Dating Sites Widows and Widowers Dating Site Xattract Dating Site Xcrushes Dating Site Yahoo Dating Site 10 Year Old Dating Site 100 Free Russian Dating Sites 100 Free Ukraine Dating Site 13 14 Year Old Dating Sites 50 Dating Sites Free 50s Dating Site 55 and Older Dating Sites 55 Dating Sites 60 Dating Sites Alt Dating Site America Dating Site Amwf Dating Site Anal Dating Site Anastasia Dating Site Login Are There Any Completely Free Dating Sites Asian Girl Dating Sites Asian Interracial Dating Sites Asian Men Dating Site Asian Singles Dating Sites B2 Dating Site B2 Dating Site Reviews Bear Dating Site Best Asian Dating Sites in Usa Best Dating Sites for College Students Best Dating Sites for Couples Best Dating Sites for Older Singles Best Dating Sites for People Over 50 Best Dating Sites Reviews Best Free Adult Dating Sites Best Free Dating Sites for Over 50 Best Free Sex Dating Sites Best Gay Dating Sites for Relationships Best Internet Dating Sites Best Japanese Dating Site Best Jewish Dating Sites Best Plus Size Dating Sites Best Rated Dating Sites Best Russian Dating Sites Best Serious Dating Sites Best Swinger Dating Sites Best Trans Dating Site Best Trans Dating Sites Biggest Dating Sites Black Lesbian Dating Sites Black Tinder Dating Site Blasian Dating Sites Blender Dating Site Brony Dating Site Celibate Dating Site Charmerly Dating Site Reviews China Cupid Dating Site Chubby Chaser Dating Site Clown Dating Site Colorado Dating Sites Completely Free Cowboy Dating Sites Completely Free Dating Sites for Over 60s Connecting Singles Dating Site Connecting Singles Free Online Dating Site for Singles Convict Dating Site Curvy Women Dating Site Da8er Dating Site Dating Site First Message Dating Site for Big Guys Dating Site for Big People Dating Site for Black Woman and White Man Dating Site for Chubby Guys Dating Site for Divorced Parents Dating Site for Gamers and Nerds Dating Site Pictures Dating Site Prices Dating Site Reviews 2019 Dating Site Singapore Dating Site Where Girl Messages First Dating Sites for Dating Sites for 10 Year Olds Dating Sites for 11 13 Year Olds 2019 Dating Sites for Animal Lovers Dating Sites for Asian Guys Dating Sites for Bisexual Women Dating Sites for Couples Looking for a Girlfriend Dating Sites for Curvy Women Dating Sites for Felons Dating Sites for Gay Women Dating Sites for Interracial Couples Dating Sites for Money Dating Sites for Professionals Over 50 Dating Sites for Widows Widowers Dating Sites Omaha Dating Sites Scotland Dating Sites Without Signing Up Demisexual Dating Site Detroit Dating Sites Donald Trump Dating Site Eharmony Christian Dating Sites Elite Singles Dating Site Reviews Facebook Dating Site Free Farmer Only Dating Site Farmers Dating Site App Farmers Dating Site Reviews Farmers Only Com Dating Site Felon Dating Site Female Dating Sites Filipina Dating Sites Free Find Hidden Profiles on Dating Sites First Algorithm Dating Site Freaky Dating Sites Free Caribbean Dating Sites Free China Dating Site Without Payment Free Colorado Dating Sites Free Country Dating Sites Free Cowboy Dating Sites Free Dating Site 2019 Free Dating Site in Usa No Credit Card Required Free Dating Site Online Chatting Free Dating Sites for Over 40 Free Dating Sites for People Over 50 Free Dating Sites Free Free Dating Sites in California Free Dating Sites in Ct Free Dating Sites in India Free Dating Sites in My Area Free Dating Sites in New York Free Dating Sites in Sacramento Free Dating Sites in Texas Free Dating Sites in the World Without Payment Free Dating Sites in Wisconsin Free Foreign Dating Sites Free Granny Dating Sites Free Hispanic Dating Sites Free Hiv Dating Sites Uk Free Hiv Dating Sites Usa Free Latin Dating Sites Free Legit Dating Sites Free Local Asian Dating Site Free Native American Indian Dating Sites Free Naughty Dating Sites Free No Registration Dating Sites Free Trucker Dating Sites Free Unblocked Dating Sites Funniest Dating Sites Gay Bear Dating Sites Gay Dating Sites in My Area Gold Digger Dating Site Good Dating Site Bios Good Online Dating Sites Hangout Dating Site Happen Dating Site Happn Dating Site High Income Dating Sites Hinge Dating Site Review Hinge Dating Site Reviews Hiv Singles Dating Site Hmong Dating Site Horny Dating Sites How Do I Stop Getting Emails From Dating Sites How to See if Someone is on a Dating Site How to See if Someone is on Dating Sites Iceland Dating Site Indonesian Dating Sites Infj Dating Site International Christian Dating Site International Dating Sites for Women Introduction Title for Dating Site Jewish Dating Sites for Seniors Jiayuan Dating Site Jolly Romance Dating Site Largest Dating Site Latinos Dating Site Law Enforcement Dating Site Legitimate Asian Dating Sites Lesbian Dating Sites in Usa Lesbian Singles Dating Sites Linkedin Dating Site List of Dating Sites on Facebook List of Free Dating Sites in the World List of Russian Dating Sites Little Armenia Dating Site Local Hookup Dating Sites Local Lesbian Dating Sites London Dating Site Looking for Dating Site Looking for Free Biker Dating Sites Love Feeling Dating Site Mackenzie Lueck Dating Site Marijuana Dating Site Matchocean Dating Site Mate Dating Site Mature Quality Singles Dating Site Login Medical Dating Site Meet Me Com Dating Site Memphis Dating Site Memphis Dating Sites Mennonite Dating Site Metal Dating Site Metal Dating Sites Metalhead Dating Site Migente Dating Site Millionairematch Millionaire Dating Sites Missouri Dating Sites Mom Dating Site Mom Dating Sites Momo Dating Site Musicians Dating Site Muslim Dating Sites for Divorcees Muslim Dating Sites Usa My Black Partner Dating Site Reviews My Dating Sites My Time Dating Site Names of American Dating Sites National Dating Site Nepali Dating Site Netherland Dating Site Netherlands Dating Sites No Charge Dating Sites No Credit Card Required Dating Sites No Login Dating Sites No Strings Attached Dating Site North Carolina Dating Sites Norway Dating Site Norwegian Dating Sites Ohio Dating Sites Older Dating Sites Free Omaha Dating Sites On Dating Site Online Sex Dating Site Orlando Dating Sites Orthodox Jewish Dating Sites Ourtime Dating Site Free Search Over 60s Dating Sites Over 70 Dating Site Pansexual Dating Sites Passion Dating Site Review Passion Search Dating Site Reviews Phone Number for Plenty of Fish Dating Site Customer Service Pittsburgh Dating Sites Play No Games Dating Site Plenty of Fish Dating Site History Plenty of Fish Dating Site Sign in Plenty of Fish Login Dating Site Poff Dating Site Polygamy Dating Sites Free Popular Online Dating Site Portland Dating Sites Pos Singles Dating Site Poz Dating Site Prison Darlings Dating Site Private Dating Sites Prof Dating Site Professional Singles Dating Site Queer Dating Sites Ranchers Dating Site Redneck Dating Site Rich Man Dating Site


https://preview.redd.it/2xivqwr2hdd51.jpg?width=275&format=pjpg&auto=webp&s=505d5d62c794514322d7c810a28f66a86ffa028c
submitted by 27JJuldacket to u/27JJuldacket [link] [comments]


2020.07.22 22:49 GhostfacexProdigy AMCI Mining SPAC Speculation

AMCI Mining SPAC Speculation
AMCI - http://amciacquisition.com/
From their website: We will focus on partners with the following qualities:
· Enterprise Value of $500mm to $1bn
· Strong, growth-oriented management team
· Robust growth profile, either organic or through acquisition
· Jurisdiction in the Americas, Australia or Europe
· Companies that are viable IPO candidates
· Recurring revenue stream and competitive cost profile
Looking to acquire a target “underpinned by a long-standing, producing operation located in one of the world’s most productive copper belts*, which is forecasted to produce in excess of 50,000 metric tons of copper in* 2021...
seek to utilize its initial asset base and financial and technical capability to pursue an aggressive growth strategy in the copper industry, including further asset development, acquisitions and industry consolidation. The Company’s management believes copper presents an attractive investment opportunity given the commodity’s significant demand growth potential, driven by copper’s use in electric vehicles, renewable energy and antimicrobial applications, and believes that copper has upside pricing potential relative to current market levels.
https://spacinsider.com/2020/05/11/amci-puts-out-teaser-on-potential-combo/
The Copper Industry Outlook:
Management:
https://preview.redd.it/t98rvzow0hc51.png?width=1571&format=png&auto=webp&s=bedb0c588a72293003d80d222512598c1a62b3ae
Details:
  • Deadline on Oct. 22nd (looks like quiet time for SPACs so good thing for AMCI)
  • 32.3% redemption's in latest vote
    • $151.9 million will remain in the trust, down from $224.5 million
  • UW team is slightly above avrg but still pretty good
    • Jeffries, UBS
  • Legal team pretty solid
    • Issuer's Counsel: Ellenoff Grossman & Schole LLP
    • Underwriter's Counsel: Skadden, Arps, Slate, Meagher & Flom LLP
  • Management is nothing spectacular but has connections in industry
  • What I do love is the industry - copper mining.
  • I would appreciate more opinions/info on management/legal/UW/copper industry
  • Anyways that stuff doesn’t matter as much as this graph below
RH catching up https://www.robintrack.net/symbol/AMCI
Institutional Holdings: https://www.nasdaq.com/market-activity/stocks/amci/institutional-holdings https://money.cnn.com/quote/shareholders/shareholders.html?symb=AMCI&subView=institutional

https://preview.redd.it/bne8lyiz0hc51.png?width=692&format=png&auto=webp&s=0ef0986e97fd006bdf7c8c78c0237443ab922758
Deutsche bank going hard – increasing their position 45,000% - WOW
Risks:
"As indicated in the accompanying financial statements, at March 31, 2020, the Company had $377,064 in cash, working capital of $410,110, and $5,399,515 of interest available to pay its tax obligations...The Company’s liquidity needs have been satisfied to date through the contribution of $25,000 from the sale of the Founder Shares, the loan from the Sponsor in an aggregate amount of $218,610 pursuant to a promissory note, and the net proceeds from the sale of the Units and the Private Placement Warrants held outside the Trust Account."
  • Its a mining play so extra risk invovled IMO
  • The LOI teaser came out a while ago with no update... what gives?
SEC Filings:
https://www.sec.gov/cgi-bin/browse-edgar?CIK=amci&owner=exclude&action=getcompany
This is my DD but I wanted to share in hopes of opening discussion and hopefully some insight from energy or mining professionals as I not yet dabbled with mining.
TLDR: Just read its not that detailed Disclaimer I own $AMCIW
submitted by GhostfacexProdigy to SPACfeed [link] [comments]


2020.07.22 22:48 Pedriklin How to Hire a Hacker for iPhone Spy Monitoring

How to Hire a Hacker for iPhone Spy Monitoring
A lot of people are looking for someone's cell phone looking for ways to gain access and think that spying or monitoring an iPhone is going to be very difficult, and they are actually not wrong to think this way. If you carry out a search for an iPhone hacking solution, you will find a lot of results claiming they will provide the solution you need in this regard.
If you try to use any of the so called iphone spy hacking solution, you will realize that most of them end up being a waste of time. They usually take you through a series of click-bait on the name of human verification and surveys. While in most cases, they fail short of what they promise to provide. Whatever the case may be, it is important that you find the best iphone spy app to get the job done.
https://preview.redd.it/dr0u5kn71hc51.png?width=760&format=png&auto=webp&s=db13e387760442a365b2a2f8d0c6daebdd150d4b
DataBurglar is the iphone monitoring spy app for iphone hacking. After many months of searching and researching thoroughly for an iPhone hacking app that works as it claims, I was eventually lucky to have stumbled upon [email protected]
How to Spy on iPhone Remotely
It has been a really hard call for most people who are in a broken relationship. For them, knowing the unknown is the only way out of the labyrinth of questions and assumptions that are tearing their lives apart. “Is my spouse cheating on me?” “Who is my husband chatting with?” “How can I catch a cheating spouse with iphone spy app?”
These are all questions that could create a serious imbalance in one’s life. Trying to get answers without any confrontation seems like the best thing to do. iPhone spy apps have been around for a while but are now in high demands these days. Over the years however, they have been improved upon to become better and more functional.
In fact, we live in a time where a lot of people are beginning to hire professional hackers for phone hacking services. How to spy on an iPhone remotely, and without touching it is another one of the many things that spy app users have been wanting. DataBurglar lets you gain remote access into any iphone or android phone giving you access to all the phone's content; call log, text messages, whatsapp, messenger, chat, social media accounts and other sensitive data .
Best iPhone Monitoring Spy App
As technology is growing vastly, securing kids from online threats has become more necessary. Kids have easy access to mobiles, laptops, and other gadgets. There is no doubting the fact that these gadgets are important for their mental growth but they somehow have disadvantages too. In order to secure your kids from internet dangers like cyberbullying, adult video, etc, using an iphone monitoring spy app usually helps.
In this section of the post, we are going to list the top 10 best iphone monitoring software apps. child monitoring applications.
The best Top 10 iPhone Monitoring Applications:
  1. DataBurglar: DataBurglar is widely recognized at the best iphone monitoring spy software. You can always easily request your customized DataBurglar iphone monitoring spy app by simply sending an email to - [email protected]
  2. Spyzie
  3. mSpy iPhone Spy App
  4. XNSpy iPhone Spy Software
  5. Flexispy
  6. Highster Mobile
  7. Spyic
  8. iSpyoo
  9. Spyera iPhone Monitoring App
  10. Spy Master Pro iPhone Monitoring
Features of DataBurglar iPhone Monitoring Spy Software
DataBurglar is without a doubt the best monitoring app for iPhone that can be used to keep track of almost everything on the target iPhone, such as SMS, call history, keystrokes, surroundings, and activities on social apps like WhatsApp, Facebook, WeChat, Viber and more. DataBurglar also allows you to limit screen time and block apps and games to ensure enough homework time and sleep time for your kids. Request DataBurglar iPhone monitoring app software by sending an email to - [email protected], and start enjoying all its features!
Some key features of DataBurglar iPhone Monitoring Spy Software Include:
Remote iPhone Monitoring: Using the remote control panel, you are allowed to change the monitoring status of DataBurglar between ON and OFF. It helps you to remotely enable or disable the monitoring status, which is helpful for you to track the GPS location of the lost phone.
Secure iPhone Monitoring: Unlike other Monitoring apps which only store your logs on an online server, DataBurglar iPhone monitoring with/without jailbreak allows you to upload/send logs to your own Email, which is more secure.
Discreet and Undetectable: It is difficult to access DataBurglar without permission since it is protected by a password and a customized access code or URL. It’s tough to uninstall it because you can configure it as a system admin or system app after rooting.
How to Hire a Hacker to Hack and Spy iPhone
When it comes to iphone hack and monitoring, your best bet is to go for iPhone Hackers for Hire solution. Hackers have all the necessary technical skills required to successfully gain access into any iphone, android phone or any other kind of cell phone. A lot of legit and verified hackers stay up to date with all the necessary update and required skills ahead with the available security updates that comes with the iOS updates.
Cell phone spying or hacking has become a thing in the mobile technology days which people really need to take seriously. We are in world where our personal lives or information could be easily leaked online through either the social media, the banking transactions, simple WI-Fi connections and other essential online transactions. There are different reasons you might need to hack a cell phone.
For instance, you might want to eavesdrop on your cheating partners phone calls, a competitor business plans,or gain access to a blackmailer's cell phone and so on. So for whatever reasons you might need to hack a phone undetected ,you should choose the right and easy way to do it.
Best iPhone Spy App Monitoring Software
DataBurglar - "[email protected]" is the most reliable and best iphone monitoring spy app. You can easily spy and monitor any iphone remotely, android hack or hack and spy on any other kind of cell phone remotely. All you need to hack the iphone is the apple id or phone number. Once the hack is completed, you will be able to login to your own personal dashboard and start monitoring the target iphone. You can also hire one of the best verified hackers for any hack request, and you can be sure the service will be delivered to your satisfaction
submitted by Pedriklin to u/Pedriklin [link] [comments]


2020.07.19 18:36 _The_Hard_Truth_ Trump Covid Timeline (March 25 - April 20)

March 25: Trump makes baseless attack on nurses, claims they are stealing equipment. Not only is there no evidence, but the explanation for increased usage is straightforward: During a pandemic *all* hospital workers (janitors, techs, foodservice employees, etc.) need PPE – not the case otherwise.
March 26: US death count is now over 1,100.
March 27: $2 trillion stimulus package signed into law (official document / breakdown of spend / chart). Key points: Unemployment insurance extended, individuals gets a small one-time payout ($1,200 per person or less), small businesses get up to $2 million in forgivable loans (but not really…) if they keep people on their payroll, a dedicated bailout for the airlines (with those who donated to Trump getting first dibs), and a $4.5 *trillion* fund for big business (leveraging the $454 billion in the bill as credit for a greater fund) – to be doled out by Secretary of the Treasury, with Inspector General oversight). Trump immediately vows to remove that oversight (official Signing Statement), which would violate the law. He makes good on this promise on April 7th.
March 29: US death count is now over 2,400. Trump Thrilled That Coronavirus Is Boosting His Press Conference Ratings
March 29: Trump says he expects 100,000 US deaths, and that 200,000 deaths would still indicate we’ve done a ‘good job’
March 30: “I haven't heard about testing in weeks. We've tested more now than any nation in the world. We've got these great tests.... I haven't heard about testing being a problem."
March 30: Trump bizarrely blames hospitals for mask and ventilator shortages. Definitely part of a larger trend.
March 30: Trump repeatedly claims (at least four times) “We inherited a broken (covid-19) test.” The virus did not exist before he took office, so (of course) there was no test then. The faulty initial test for the coronavirus was created during Trump's administration, in early 2020, by the CDC.
March 30: Asked about the expansion of mail-in voting (with so much of the country in lockdown), Trump says Republicans would ‘never’ be elected again if it was easier to vote.
March 31: Trump, when asked why the US is not testing (per capita) as many people as South Korea, “It’s very much on par.” It’s not. Embarrassingly so.
March 31: “I know South Korea better than anybody. It’s a very tight. Do you know how many people are in Seoul? Do you know how big the city of Seoul is? 38 million people. Bigger than anything we have. 38 million people all tightly wound together.” Seoul has just under 10 million people. Wonder where that came from?
April 1: Journalists are skipping Trump’s daily coronavirus briefings, citing a lack of information and an abundance of campaigning.
April 1: US death count is now over 5,000. 1,000+ people are now dying per day, over twice the rate of the flu – and death rates are still doubling every 3-5 days.
April 2: Pence Denies Trump Ever Downplayed the Coronavirus
April 2: Networks refuse to carry Trump’s daily coronavirus press briefings, saying they have little news value and are basically campaign rallies.
April 2: The Labor Department announces that 6.6 million Americans filed jobless claims through the end of March, bringing the two week total to 10 million. Trump responds “It’s not like we have a massive recession…
April 3: Trump fires the Intelligence Inspector General, the watchdog who sparked the impeachment process, who publicly states he was fired for doing his job. Even Republican leaders are asking for an explanation.
April 3: Jared Kushner, taking a greater role in managing medical supply chains in response to the virus, declares that stockpiles of much-needed supplies (PPE, ventilators, etc.) governors were requesting to help with the coronavirus pandemic aren’t meant for the states (video), but instead for private corporations that will sell them to the highest bidding states. Four days later it comes out that Feds are seizing PPE directly from hospitals, with hospital leaders unable to get answers as to where the PPE is going. Some in Congress believe it is going to Trump’s allies. They prioritized tips and bids from close Trump associates rather than experienced/legitimate vendors, which predictably led to some bad deals.
April 3: Trump orders PPE manufacturers to stop shipping to other countries. 3M publicly rebukes him (official statement) and ignores the order, and Canada’s Prime Minister threatens retaliation.
April 3: From this point forward, at least 10,000 people in the US will die from the virus each week. The following week more than 15,000 will die, and the week after that more than 19,000 will die.
April 4: Governors confirm that Trump is selling PPE to private companies (McKesson Corp., Owens & Minor, Cardinal Health, Medline Industries, etc. These companies receive an antitrust waiver on Saturday, so they can coordinate pricing (to maximize profit) across state lines.
April: The Trump administration pays a bankrupt company with zero employees $55 million for N95 masks, which it's never manufactured. Why? Likely, that company is going to buy masks from the seized federal pool for $0.64 each and sell them to the government for $5.00+ each, using the profit to pay outstanding company debts. Since the money repays a "debt", it cannot be feasibly recovered in the future since it has already been paid to someone else (guy that loaned the company his own money, Trump's buddies, Russians etc.) Being loan repayments, the payouts are difficult to legally prove are "kickbacks."
April 4: Only one official has been fired over the virus – the captain of an aircraft carrier who pleaded to let his infected ship dock so his infected men could go into isolation. The captain tests positive for the virus. The secretary of the Navy flies 8,000 miles to Guam to publicly humiliate the captain over the carrier’s PA system, and is forced to resign a couple days later. By April 12th, over 600 sailors will be infected before the ship is (mostly) evacuated. 850 will be infected in total. The first sailor from the ship will die on April 13th. Captain Crozier will be restored to duty on April 24th.
April 5: Administration officials are telling reporters that, with his corona policies, ‘Trump is killing his own supporters’.
April 6: Trump cuts off Dr. Fauci during a briefing when he attempts to answer a reporter’s question about Hydroxychloroquine; a White House meeting erupts afterward where Dr. Fauci is attacked for disagreeing with the president. Trump’s enthusiasm for the drug is reported to be from Dr Oz. and Rudy Giuliani. Trump’s information is incorrect. Two weeks later the FDA will issue warnings on the drug as ‘serious poisoning and death’ reported, and that patients receive no benefit and have a higher death rate taking hydroxychloroquine for the virus.
April 7: Trump effectively removes the stimulus oversight role by replacing the Inspector General with a loyalist. This gives Trump unfettered access to, through Secretary Mnuchin, dole out $4.5 Trillion (more than the *entire* Federal budget) to whoever he wants.
April 7: Trump publicly states that he is considering cutting off US funds to the World Health Organization, saying they missed the call” and were months late warning about the virus (WHO warned that the global risk from SARS-CoV-2 was high on January 23rd, and declared a global health emergency on January 30th).
April 7: Two more Republican Senators found profiteering on Inside corona info - Senator Perdue (R – GA) bought $185,000 in PPE stock and that Senator Burr (R – SC, the guy who told his donors to sell) also sold shares in a company just before sanctions were imposed that crushed the stock price.
April 8: Wisconsin holds their in-person Democratic primary during lockdown, with extensions for mail-in / absentee ballots being rejected by the Republican WI legislature and the US Supreme Court. Over a million people applied for ballots, but most were not even sent to voters by election day, particularly in “blue” counties. There were very few open polls: Milwaukee, for instance, has 600,000 people and *five* polling stations (down from 180). Wait times were over four hours as polls opened, and increased as the day went on. In addition to being obvious voter suppression (“'One of the Most Brazen Acts of Voter Suppression in Modern Times'”, per the US Supreme Court dissenting opinion), it will result in the direct & unavoidable outcome of more COVID-19 cases and deaths. Ironically, the Republicans in the WI legislature and the WI Supreme Court voted absentee to make this decision because they determined that it wasn't safe to meet in person to vote on it. This is considered to be a trial run for the election in November. The debacle backfires for Wisconsin republicans, who fail to hold onto a key state Supreme Court seat.
April 9: Trump denounces mail votes as corrupt – before admitting he applied for one (and ignoring that there is over a century of precedent). Most Americans want mail-in ballots; Trump admits he is against them because more inclusive voting is bad for Republicans. Trump lies about voter fraud while his own CDC encourages mail-in ballots and voter support for mail-in ballots continues to increase.
April 9: The Labor Department announces that another 6.6 million Americans filed jobless claims through April 3rd, bringing the recent total to 16.8 million. Trump boasts about stock market gains.
April 9: Pence's office says it will block experts such as Dr. Fauci from appearing on CNN until the networks agree to televise the portion of the White House briefings that include the president / vice president. Reverses course when called out.
April 10: Trump tweets about ratings for his coronavirus press briefings for the 3rd day in a row as US death toll surpasses 18,000 and unemployment nears 17 million.
April 10: Trump claims unconstitutional power to overrule state stay-at-home orders, as falling re-election polls drive him to want to prematurely re-open the economy.
April 11: Chief medical officer on the White House's coronavirus task force, Dr. Deborah Birx tells administration officials that the virus would most likely soon go away
April 11: New York Times publishes major article on Trump’s handling of the virus. Trump is enraged.
April 11: The Postal Service announces bankruptcy by September without assistance (above, Trump explicitly banned $13 billion for the USPS in the stimulus package). Voices from all sides proclaim that the Post Office must remain viable. His motivation seems to be (seriously) jealousy of Jeff Bezos.
.
April 11: Trump shows that he still doesn’t know the difference between bacteria and a virus; says ‘germ is so brilliant antibiotics can’t keep up with it’ in chaotic White House briefing – describes the virus as ‘very smart’, ‘a brilliant enemy’, and ‘a genius’, on same day more than 2,000 US citizens die.
April 13: Trump claims he has “total” authority as US president and insisted he had the power to lift coronavirus restrictions despite the nation’s constitution leaving such rights to state governors. Constitutional experts disagree. The CDC and FEMA warn of a significant chance of resurgence. Even Fox News anchors see the problem.
April 13: Governors respond by pointing out that the United States is not a monarchy, that they will ignore any orders to re-open while they feel it’s unsafe, start to form regional alliances to coordinate their respective reopening, publicly state they expect no further help from the federal government, and organize secret flights to bring masks and gloves from China out of fear Trump would seize them (unfortunately, this doesn’t always go well.)
April 13: Networks continue to not cover or to cut away from his press briefings; CNN cuts away from this one with the chyron “Angry Trump turns briefing into propaganda session”. MSNBC cut away as well. Coverage of the briefings has changed from covering the news around the virus to covering Trump’s increasingly crazy antics.
April 13: Number of diagnosed cases of the novel coronavirus: 555,371, though experts believe the real number is far higher due to under-testing. Number of deaths: 22,056, though experts believe the real number is far higher because of people who die at home or have their deaths misclassified (in mid-May, Dr. Fauci says the same.) Number of newly unemployed: 17 million, though experts believe it's likely higher because so many laid-off workers were unable to file for unemployment.
April 14: Trump cuts off US funding to the World Health Organization, says "I am directing my administration to halt funding while a review is conducted to access the World Health Organization's role in severely mismanaging and covering upthe spreadof the coronavirus," While the largest contributor to the WHO’s budget, the amount he is stopping is less than half of what he has spent on golf outings since becoming president… during which time (3+ years) he has failed to appoint a US Representative to the WHO.
April 15: Trump delays printing of Stimulus checks to get his name printed on each one.
April 15: It’s revealed that Senate Republicans snuck a $90 billion tax cut for millionaires into the stimulus package. Over 43,000 US millionaires will get ‘stimulus’ averaging $1.6 million each. “For those earning $1 million annually, a tax break buried in the recent coronavirus relief legislation is so generous that its total cost is more than total new funding for all hospitals in America and more than the total provided to all state and local governments,” Billionaires are now $280 billion richer since the start of the pandemic.
April 15: Trump threatens to adjourn both chambers of congress (allowable under the constitution only under conditions that are not met) to unilaterally install judges and political nominees - something no president has ever done. There is little doubt where this is coming from.
April 15: Protests against stay at home policies occur in several states are organized by an group linked to the DeVos family and guns rights groups. Fox defends even the fringe protesters. And there are a lot of them. Less than 24 hours after stating that the decision to ease restrictions was up to governors (and just two minutes after Fox News airs a segment on the protests) Trump tells protesters to ‘Liberate’ their (democrat) states and lends support to the protesters. Governors accuse Trump of encouraging ‘domestic rebellion’; and experts agree. Protests will continue and expand over the next few weeks, with increasingly bad elements at many rallies, leading to fears of violence.
A few weeks later, 72 people in Wisconsin test positive after attending one of these 'large gatherings'… and Michigan’s governor warns Pence that anti-lockdown protesters are spreading the virus to rural areas.
April 15: White House snubs Azar, installs Trump loyalist Michael Caputo as Health and Human Services (HHS) spokesperson.
April 16: The Labor Department announces that another 5.2 million Americans filed jobless claims in the week ending April 10th, bringing the four week official total to 22 million, or 13.5% of the labor force.
April 17: Trump calls for reopening America’s gyms (germs?) one day after call with SoulCycle’s owner, who happens to be a big supporter that recently had a Trump fundraiser. A big one.
April 18: Trump ridicules social distancing at Air Force Academy commencement as 'Politically Correct'.
April 18: Trump boasts he likely saved ‘billions’ of lives in a nation with 330 million people.
April 19: Trump brands FBI top brass ‘human scum’, calls CNN reporter ‘brainless’, and says he’s ‘not a fan’ of Mitt Romney in freewheeling press conference.
April 20: Trump tweets that he will, through executive order, ‘suspend immigration’ into the U.S – parroting Fox News talking points. The USCIS has been closed since March 18, 2020, so practically this was already in effect.
April 20: Government Accountability Office (GAO) launches 30+ separate coronavirus Stimulus related audits, striving to bring accountability to fund dispersal.
submitted by _The_Hard_Truth_ to Trump_Covid_Timeline [link] [comments]


2020.07.13 15:02 packym How to fix Twitter... If I Ruled the Tweets

Sorry for the self-promo, but I think this crew is going to like this. My thoughts on how to fix Twitter...
(Original post here: https://notboring.substack.com/p/if-i-ruled-the-tweets)
On April 7th, just weeks into the Coronavirus pandemic, Twitter and Square CEO Jack Dorsey announced that he was giving away $1 billion to fund global COVID-19 relief. The world applauded Dorsey like this level of generosity was something new for him. Anyone who’s been following Twitter, though, knows that Jack Dorsey has been giving away value for years.
Twitter is the most undermonetized product in the world, because it doesn’t know what it is. For someone so into meditation, u/jack’s lack of self-awareness is a surprising error with major implications.
But Twitter still has a shot. One decision in 2015, and the company’s soporific product cadence since, was a blessing in disguise that gives Twitter a blank slate to build the product that it was meant to be all along.
Sliding Vines
In her recent book on Instagram, No Filter, Sarah Frier includes one paragraph about the 2015 battle between Vine, Twitter’s six-second video app, and its biggest stars:
Twenty of the top Viners banded together to negotiate with Twitter, saying that for about $1 million each, they could post every day for the next six months. If Twitter rejected the deal, they would instead start posting Vines to tell followers to find them on Instagram, YouTube, or Snapchat instead. Twitter refused, the stars abandoned the app, and eventually, Vine shut down entirely.
That short paragraph represents one of the major Sliding Doors moments in recent tech history. What does the app world - Facebook, Instagram, Twitter, TikTok, Netflix, and more - look like if Twitter had given into its biggest stars’ demands?
Sliding Doors moments are what-ifs based on small tweaks to the timeline, popularized by the 1998 Gwenyth Paltrow banger, … Sliding Doors.
The movie runs two timelines in parallel, split by one moment in which Paltrow’s character, Helen Quilly, either misses or catches her train home.
In Timeline 1, Helen misses the train, gets mugged, hits her head, and finally gets home just as her fiancé’s ex drives off, none the wiser that the two had just slept together.
In Timeline 2, Helen jams her shoulder between the “sliding doors,” catches her train, and makes it home to catch her fiancé in bed with another woman.
As the short-form video app TikTok sweeps the world - it is expected to generate $500 million this year in the US alone - Twitter’s critics are running the sliding doors scenario on the company’s 2015 decision to effectively kill its own short-form video app.
In Timeline 1, Twitter plays ball with the Viners. It pays them what they want, listens to their product feedback, and turns Vine into what TikTok is today. Twitter is an engagement powerhouse.
We’re living in Timeline 2. Twitter says no to the Viners and ultimately shutters the app. Its main product stagnates and its stock price follows suit. TikTok fills the void and its parent company, ByteDance, is worth 4x as much as Twitter, with a valuation rumored to be between $105-110 billion on 2019 net profits of $3 billion - nearly as much as Twitter’s total 2019 revenue!
But there’s a twist in Sliding Doors, and it applies to Twitter, too.
In Timeline 1, the one in which she stays with her fiancé, Helen is miserable.
In Timeline 2, after a couple of days of deep sadness and lots of drinks, Helen cuts her hair, starts her own PR firm, and falls in love with a much better guy.
Timeline 2, the one that seems like it would be worse for Helen, allows her to rediscover who she is. Her new path ends up being so much better than the one she was originally on, because Timeline 1 Helen wasn’t her best self after all.
(Let’s ignore the part where Helen gets hit by a van and dies. Life is unpredictable!)
Twitter’s Timeline 2 has the potential to be so much better than Timeline 1, but the company is still in the midst of a five-year post-breakup funk. Since it hasn’t rediscovered itself yet, I’m going to play the role of “concerned best friend” and help Twitter snap out of it.
If Twitter had kept Vine alive, it would have set a bad precedent, giving into creators’ demands and paying them off while failing to capture value itself. Even worse, it would have allowed Twitter to continue to delude itself into thinking that it’s a social network.
Here’s the thing:
Twitter thinks it’s Facebook, but it’s LinkedIn.
Twitter thinks it’s an ad product, but it’s a subscription product. It thinks it’s an Aggregator, but it’s a Platform. It thinks it’s a social network, but it’s a professional network: one built for the Passion Economy, based on the strength of ideas instead of past experience.
That realization should be liberating for Twitter and Jack Dorsey. Instead of being the world’s least innovative social network, it can be its most innovative professional network. Twitter should be the beating heart of the Passion Economy, and begin capturing some of the tremendous value it creates.
Today, we’re going to give Twitter a makeover with its new identity in mind.
Twitter is the most undermonetized product in the world. IT’S TIME TO MONETIZE!

What’s Wrong with Twitter?

Twitter is simultaneously my favorite product and the company that most frustrates me.
As a Twitter user, I love the product.
According to my Weekly Screen Time Report, I spend 5x more time on Twitter than I do on any other app. Not Boring would not grow the way it does without Twitter. I meet and talk to people I would otherwise just read about and admire from afar. If anything, I want to be able to do more on Twitter.
As a Twitter shareholder, I can’t stand the company.
Twitter’s stock has underperformed all of its peers… significantly. Twitter is down 14% since its 2013 IPO. Its next closest competitor, Google, is up 186% over the same period. Facebook, lacking scruples in its pursuit of Rubles, has more than quadrupled.
📷
So I have a lot of thoughts about what Twitter should do. I’m not alone. On Friday, I asked this question (on Twitter of course):
📷Packy McCormick @packyMIf you woke up tomorrow as @jack and could do anything you wanted with Twitter - products, features, biz model, acquisitions, go wild! - what would you do? (Note: Don’t say edit button, you’re more creative than that)
July 10th 2020
40 Retweets351 Likes
I’ve never gotten more engagement on a tweet. Twitter users love talking about what they would do to fix Twitter.
Responses ranged from “Sell the company” to “Ban the Nazis,” from “Remove the bots” to “Fix search.” Nikhil begged: “fix DMs holy shit nothing else matters please jack i beg you why are they so bad.” People asked for a podcast app, the ability to write longer-form content, and verification. Even Y Combinator founder Paul Graham got involved:
📷Paul Graham @[email protected] @jack I'd try to make Twitter less toxic. For example, I'd study how Twitter mobs form and add measures to slow them down. I'd spend a lot of time thinking about ways to make more money to compensate for the decreased engagement. (The root of the toxicity is chasing engagement.)
July 11th 2020
59 Retweets1,026 Likes
Reading through all of the responses, a pattern emerged: Twitter is terrible at being an ad-based social network, and isn’t giving Creators a pro subscription product they would happily pay for.
Social versus Professional Networks
Incentives shape behavior, both on the company and individual level.
Social networks - like Facebook, Instagram, and Snap - work by getting you and all of your friends in one place, keeping all of you engaged, and selling your attention to its real customers - advertisers. Facebook generates 98.5% of its revenue from ads.
To PG’s point, engagement-chasing leads to toxicity. Social networks are incentivized to show user growth (which disincentivizes, say, removing bots from the platform) and to keep users in the app (and outrage is a great way to keep people glued to their screens).
Professional networks - like LinkedIn - like engagement and ad revenue, too. Who doesn’t? But ads are not their main source of income. Before Microsoft bought it for $27 billion in 2016, LinkedIn made money in three ways: Talent Solutions (recruiting and learning tools, 65%), Marketing Solutions (ads, 18%), and Premium Subscriptions (want to see who viewed your profile? 17%). Only 18% of LinkedIn’s revenue comes from ads; 82% comes from subscriptions.
Professional networks aim to deliver measurable value to as many of the best companies and top people as possible, and get them to pay directly for that value. Bots and outrage are harmful to professional networks, because they make it less likely that users achieve the things they are willing to pay for to achieve - hiring, partnering, and selling.
Twitter makes money like a social network: Advertising Services (ads, 86.5%) and Data Licensing (selling companies a firehose of Twitter data, 13.5%). It generates revenue by keeping people engaged, generating data on them, and either using that data to sell ads or selling the data itself.
But Twitter isn’t very good at the business of being a social network. Twitter has long struggled to grow or monetize its user base. In 2019, Twitter made $3.4 billion from 330 million users. Facebook made $70.7 billion off of 2.5 billion users.
Facebook is for everyone who has friends, family and an internet connection, which is pretty much everyone. Twitter is not for everyone. It’s for knowledge workers who rely on Twitter to exchange ideas, promote their work, and take place in the global, real-time conversation.
That is definitionally a smaller target market than Facebook’s, but that doesn’t mean that Twitter needs to be a smaller business. Twitter’s audience is more targeted and professional; it should be able to generate more revenue per user than Facebook does. Arguably, Twitter actually does create more value than Facebook. Its lack of self-awareness, though, prevents it from capturing that value.
The Informal Bill Gates Line
Twitter is a charity masquerading as a for-profit business.
It’s nearly impossible to calculate the total value that Twitter has created for its power users - both individuals and companies - by giving them a place to build an audience, connect directly with fans, and promote their work. And Twitter keeps almost none of that value for itself.
Let’s take Substack as an example.
Substack would not exist, at least not in its current venture-backed form, without Twitter. I surveyed a group of newsletter writers about how they grow their audiences, and 95% of them use Twitter. For Substack, that’s incredible. Its customers - writers - write on Substack, share what they write on Twitter, and take advantage of Twitter’s graph to find new subscribers. Some percentage of those subscribers pay the writer and Substack takes a cut. Other writers see Substack on Twitter and decide to start their own Substack, and the cycle starts again.
Who’s capturing the value here?
The writer captures value in the form of a new free or paid subscriber.
Substack captures value in the form of new paid subscribers and new writers.
Twitter captures almost zero value. You could argue that it captures a little in the form of increased engagement that it can sell ads against, but when one of its users sees a Substack post and clicks the link, she leaves Twitter and gives her attention to Substack.
📷
This happens millions of times each day, for thousands of non-Twitter products - YouTube, Medium, The New York Times, Spotify, podcasts. Don’t get me started on podcasts. In-app podcast discovery is notoriously awful. You know where people discover podcasts? Twitter. Countless media and tech companies and personalities amplify themselves on Twitter, for free, and then bring users off of Twitter and into their product.
This is how Aggregators work. They aggregate demand, and collect a tax for sending that demand to its final destination. Every time I search on Google, for example, if I find what I want, I leave Google. But Google collects money from the company to whom I divert my attention.
Twitter is terrible at collecting that tax. Its Promoted Tweets are a hard-to-use joke. Twitter is a very bad Aggregator.
The other way of looking at Twitter is as the Platform that is further above the Bill Gates Line than any other platform on earth.
The Bill Gates Line is a phrase coined by Ben Thompson based on a Bill Gates quote about Facebook Platform:
This isn’t a platform. A platform is when the economic value of everybody that uses it, exceeds the value of the company that creates it. Then it’s a platform.
By that measure, Twitter is definitely a platform, but it’s an informal one. Whereas developers build directly on top of traditional platforms, like Windows, the businesses built “on top of” Twitter, like Substack, do so informally and without Twitter capturing any value.
Twitter is so far above the Bill Gates Line that it’s much closer to another Bill Gates Line - the world-record $35 billion that Gates has given away through the Gates Foundation.
It is time for Twitter to start capturing the value that it creates, improve its experience for its customers, and get its stock moving. For that, it needs to understand who its customer is, and what the Job to be Done is for those customers.

Who is Twitter’s Customer?

There’s a phrase that goes back to the pre-internet era that people apply to social media:
“If you’re not paying for the product, you are the product.”
It means that ad-supported businesses sell your attention (the product) to advertisers (the customer).
On social networks, users are the product, and advertisers are the customers. In non-ad supported businesses - from subscriptions to hardware to food - the product is the product, and the buyer is the customer.
On professional networks, like LinkedIn, most users are the product, but power users are the customers. Anyone can use LinkedIn for free, but users who need more capabilities - who want to recruit beyond their own network, see who’s viewing their profiles, or reach out to qualified leads - can pay for additional functionality. Like a social network, everyone on LinkedIn benefits from more people being on LinkedIn, but certain people and companies can pay to benefit more.
For Twitter, its customers are Creators, the 10% of users who generate 80% of the tweets.
Twitter should adopt LinkedIn’s model - keeping the current Twitter product free, open, and ad-supported for casual users, and charging its customers - the Creators who rely on Twitter to build and grow their businesses - for advanced tools.
What is Twitter’s Customers’ Job To Be Done?
The "Jobs to be done" (JTBD) framework, developed by Clayton Christensen, says that customers hire products to do a certain job for them. For Netflix, the JBTD is “I need to be entertained.” For Facebook, it’s “I need to connect with friends and family.” For Google, it’s “I need to find something on the internet.”
What is Twitter’s JTBD for Creators? “I need to get my ideas in front of people.”
Twitter is the Platform for Ideas. Its customers are the Creators who create and share ideas. It should diversify its revenue stream away from ads-only by adding a subscription product and monetization options for those Creators.
I’m not the first to suggest that Twitter should launch a subscription. Last week, a Twitter job posting suggesting that the company is hiring for a subscription product shot around the internet. Its stock popped 7%. Professor Scott Galloway previously wrote that Twitter should buy up dying media companies and also charge verified users a monthly fee based on their follower count, or something.
But the Prof is just as confused as Jack. A half-baked subscription product that extorts Twitter’s top users based on the follower counts they’ve spent years building up doesn’t make any damn sense.
Thanks to the 300+ replies with suggestions for improving Twitter, though, we’re ready to Play Fantasy Jack.

If I Ruled the Tweets

As @Post_Market said, “Twitter is the town hall.” That’s a wonderful thing, but real business doesn’t get done in the town halls. It gets done in the back rooms. Currently, those back rooms are off of Twitter. Jack needs to take them back.
The Fantasy Jack Twitter Roadmap is all about making it easier to create, share, and monetize great ideas, build communities, and capture value:
  1. Table Stakes: Verify identity to clean up the conversation.
  2. Twitter+ Subscription: Paid tools for Creators to find, create, and share ideas.
  3. Twitter Create: Twitter should be the place to build subscription businesses.
  4. Profiles as Creators’ Home: Develop the most underdeveloped real estate online.
This roadmap seems like a bold departure from the Twitter we know and love, but it really just represents Twitter getting out of its own way and building better versions of the things that happen outside of its control today.
1. Verify Identity and Allow Filtering by Verified
This is table stakes.
A social Aggregator might not want to verify users, creating two classes, one of which is far less valuable to advertisers, and exposing that its user base is smaller than it looks. A professional Platform for Ideas absolutely should.
Twitter used to verify its users - giving them a blue check on their profile - until it caused an uproar in 2017 by verifying a white supremacist. Now it only verifies some people, occasionally, through a non-public process that involves getting in touch with someone at Twitter. It’s messy.
Dror suggests that Twitter should “give people a chance to verify their identity, even for a small fee” and “allow filtering of posts, comments, and notifications by verified.”
The ability to filter by verified solves the bot problem, squashes trolls, and raises the level of discourse on Twitter. To PG’s point, when you’re not optimizing for Daily Active Users (DAUs) and engagement alone, you can lower toxicity.
2. Build Twitter+, a Subscription Product for Creators
Charging the most popular Twitter accounts a monthly fee based on their follower count is a progressive tax that could lead to a mass exodus. That’s not the move. But Twitter should absolutely build a Pro subscription offering for its Creators.
The subscription product should enable creators to do the JTBD better - generate, create, and share ideas - spark conversations around those ideas, and get paid for them. As a Twitter Creator, I would pay for:
Twitter is in a position to create the ultimate Creator bundle, and add to it over time. Live presentations, Superpeer functionality, free promoted tweets - the bundle would only get more valuable over time.
At $20/month (Roam alone is $15/month), Twitter+ is a $1 billion annual opportunity, without assuming that the improved offering attracts new users.
📷
3. Build, Buy, or Partner on Products for Creating, Sharing, and Monetizing Ideas
This is where Twitter takes back the value that it creates for so many other companies. It needs to get a little mean to make that happen.
Twitter is the place that Creators go to grow subscription businesses. Twitter Create should be the place that they go to build subscription businesses.
To start, Twitter should build a monetization product for Creators to easily collect subscription or one-time payments, from which Twitter takes a small cut. Instead of a Memberful plug-in on a Squarespace website, Creators should just build it all on Twitter.
Some people have suggested that Substack, which makes it easy to create a subscription newsletter, is the paywall for Twitter, and that Twitter should buy Substack. That’s crazy. Substack has raised $17 million dollars, which means that it would cost Twitter well over $100 million to acquire the company. Twitter can recreate Substack for much less than $100 million, with better functionality.
Twitter should build its own blogging and newsletter product, with a text editor, email send, analytics, referrals, custom domains, an ad-network, and easy ways for writers to grow their lists by selling promoted tweets based on follower and subscriber lookalikes, and the interest graph.
Additionally, Alex Carter suggested that Twitter should build a standalone podcasting app. That’s one approach, and it makes a lot of sense. It’s hard to share clips, notes, or anything other than an entire podcast, and Twitter could improve that.
Another approach would be to team up with Spotify. Spotify has spent a lot of money to acquire valuable IP like Gimlet, The Ringer, Joe Rogan, Kim Kardashian, and The Obamas, and is working on building out a podcast ad network. Spotify would expand its reach and improve targeting, and Twitter would earn some of the revenue it helps Spotify generate.
Why would Spotify do that? Remember, Twitter’s mean in this scenario 😈. Spotify links don’t preview anymore? Oops. Podcast discovery happens on Twitter, and Twitter should capitalize on that.
Beyond newsletters and podcasts, Twitter can give Creators myriad ways to monetize: storefronts, an expert network, paid communities, access to audio-only rooms, online events, and more. Creators might even sell bundles of their own offerings to superfans, and automatically give discounts based on retweets and referrals. Twitter is in the strongest position to integrate payments and growth, and let Creators do the rest.
Based on very rough math, this could be a $2 billion opportunity for Twitter almost immediately. Nothing would expand the Creator TAM more quickly than Twitter getting this right.
4. Make Profiles Incredible Places to Hangout
Twitter Profiles are the most underdeveloped real estate on the internet. Right now, when you click on someone’s profile, you see 160 characters on them and their most recent tweets. It’s such a huge miss. Because it’s not in the main feed, Twitter should be a lot more experimental with Profiles. Someone’s Twitter profile should be a glimpse into their world, and Twitter should both create its own features and open up its API to make that happen.
Imagine clicking on my Profile and popping into a Roadtrip experience. I’m DJ’ing my favorite songs and we’re having a conversation about the day’s tech news. People that I follow can join for free, non-follows could pay me a small fee.
I could highlight what I’m reading (assuming someone finally makes a better Goodreads), my NewsletterStack, my favorite Spotify podcasts, and the products I recently hunted on ProductHunt. I could invite accredited investors to join the Not Boring Syndicate, and show off the performance of the Not Boring Portfolio.
My Twitter Profile would be what a LinkedIn Profile would be if it were a living, breathing thing, created in and for 2020, based on what I’m currently creating and consuming.
Of course, since I’d host my newsletter on Twitter Create, there would be a subscribe button front and center, with links to the three most recent posts. If you enjoy your experience in my little corner of Twitter, you could hit a button to tip me so that I can keep creating.
Oh yeah, and with all of that engagement, maybe Twitter could even build an ad network to let relevant companies sponsor my profile, finally creating an ad product that makes sense 😉
Hit the Road(map), Jack!
Twitter dodged a bullet five years ago when it refused to pay Vine’s stars. It’s not a social network, and it’s not a product for passive entertainment. By not building in that direction for the past five years, Twitter left itself a clean slate on which to build a product for its real customers.
Twitter is a professional network for the Creators whose ideas and products shape the conversation and the world. It should be proud of that. Twitter needs to get its swagger back, and a full reset on priorities and a bold new vision would do just that.
The path that I laid out has the potential to double revenue in short order, and we didn’t even have time to cover how companies might engage with all of the new functionality that Twitter builds for its creators. Company profiles with Shopify integrations would be so clean.
I’m bullish on Twitter if for no other reason than how much I and so many others still love and rely on it, despite all of its shortcomings. Twitter creates so much value, and it’s time that it captures it.
Jack - if you have any questions, you can find me @ packym, on Twitter.
submitted by packym to Twitter [link] [comments]


2020.07.03 21:30 RebeccaNobody My Whole Story. Am I trans? Should I have transitioned?

TL;DR: Grew up thinking I had to be a woman because of having boobs and a tiny penis, started HRT at 30, 35 now and horribly depressed worrying I made a bad decision.
I'm Rebecca, I'm 35, and I was assigned male at birth. I have been on HRT for five and a half years now. For the last couple of weeks I've been seriously regretting my transition, and worrying that I'm not actually trans at all. I keep worrying that my extant depression is being exacerbated by my hormones, and that that itself is a red flag that I'm not trans and should not be taking them. This is my story, and it's going to be long. I'm sorry, but I do think it's important to get the entire background.
I started crossdressing at the age of 12 just to see what it felt like. There was a text-based game on AOL at the time called Modus Operandi, and the height of hilarity to me was dressing my male character as a woman. That got me curious as to what it really felt like. Also at this same time, I had gynecomastia, and in school I was often made fun of and told I should wear a bra. So that's what I started with when I started crossdressing. And I liked it a lot. It just felt good.
So anytime my parents were out I seized the opportunity to dress up and then go online and get more information about crossdressers and trans women. Once I learned that transition was possible, I started thinking about it constantly. Not a day went by where I didn't fantasize about taking hormones, looking more feminine, and going to school as a girl. I already had breasts, so I was part way there.
In addition to my breasts being a focal point of exploring my gender, I also had (and of course still have) a very small penis. I don't know if it qualifies as micropenis, but I wouldn't be surprised. All through puberty I kept waiting for it to grow, but...it didn't. At all. So that also added fuel to my mental fire that maybe I was supposed to be a woman. Why would God (who I don't believe in anymore) give me these breasts and a small penis if I wasn't supposed to transition?
As I got into high school, I started exploring my sexuality. I figured that while I found women attractive, I wouldn't be able to physically have sex with them, so I had better learn to like sex with men - otherwise I wouldn't be able to have sex at all. I had profiles on AOL and Yahoo as a crossdressing teen, which of course lots of creepy older men loved. And, frankly, I liked the attention from them. And I enjoyed cybersex with them. And then later enjoyed phone sex with them. And when I turned 17 I invited a guy from Yahoo over when my parents were out, I dressed up for him, and he became my first sexual experience. And I did actually enjoy it, so I was pretty confident in labeling myself as bi, which I still consider myself to be.
In college I started crossdressing more, and going to the college LGBT club, but I never went any farther than that. I was afraid to date women lest I be rejected by them for the size of my penis, and I was afraid to date men because of what my conservative Catholic parents would think. Once I turned 23, I went on a diet, lost quite a bit of weight (still had the breasts, though. they just shrank a little), and gained some confidence and started dating women. I got my first girlfriend at age 24 in 2009, and she was the first woman I ever had sex with. It was okay.
A year later, we were laying around in bed one day, and she asked me to say one thing I disliked about her. I initially refused because I'm not a complete idiot, I knew damn well it was a trap. She persisted, and ultimately I relented and told her that I didn't like how she frequently complained to me about things that were out of my control. She then immediately blurted "Your penis is too small!" which sort of proved my point about her complaining about things out of my control. But that killed my desire for sex forever. I still think about her and what she said every day (not an exaggeration). If I do detransition, there's no way I could ever have sex with a woman again.
Anyway, between her harsh words and the antidepressants I started taking in 2011, I completely lost interest in sex with her. Basically just to shut her up and prevent her from complaining even more, I'd fantasize about myself as a woman to get as erect as I possibly could, finagle my way inside of her, and then proceed to have sex for what I felt was an appropriate time before I got tired and faked an orgasm so I could stop. Yes, I, the "man," was the one who faked orgasms. I just didn't want to do it.
We eventually broke up the day after Thanksgiving in 2013. I was living on my own in another state by this point in my life, and was unemployed, so with her out of the picture and lots of free time I decided I could resume exploring my crossdressing (which I had continued to do off-and-on this entire time). I met someone online who lived in the same town, was slightly older than me, and also crossdressed. She was setting up a queer-friendly D&D group and wanted me to join. I did, and now I had a friend to dress up and hang out and go shopping and do whatever with. I also leaned more into sex with men at this point, as it was just easier to deal with. I could be the receptive partner, and I wouldn't have to even think about my penis. Win-win.
In mid 2014 I started going to an LGBT nightclub an hour away, and really enjoyed myself. I so happened to meet another crossdresser while smoking outside, and we started talking, and she brought me into the support group she was with. I started going out as Rebecca regularly, and got nicer clothes, a better wig, and started getting better with makeup. At this same time, I started talking with a Canadian trans woman I found on reddit. I have a weird obsession/fascination with Canada, and she was also a Mets fan, so I asked if she was single. She said "That depends. Are you a woman?" and I semi-jokingly replied "No, but I'm willing."
She was the one who told me about informed consent and DIY hormones. I was still going on the information I looked up as a teen in the late 90s about needing a therapist and a year-long real life test. That had always dissuaded me from really exploring transition. But now I learned it was actually possible and fairly easy. And living alone I didn't have to worry about my parents' opinion. So after a few months of thinking about it, I ordered some E and spiro online and started taking it in a very low dose, just to test for any reactions/side-effects.
January 8, 2015 I started HRT in earnest. It was a very low point in my life, so I had nothing to lose. I figured either I'd like being a girl or I'd go with my original plan of killing myself (I had never envisioned living past 30). My depression actually got worse and worse. And in April my mom came up to visit me, and she saw my makeup and my pierced ears and put 2 and 2 together. She disapproved, but said she couldn't stop me, and that made my depression worse. By June she and my dad were afraid of my safety and made me move back in with them on the condition that I couldn't be Rebecca in their house. So I only got to be Rebecca one day a week at my support group, all while still taking hormones. By this point I had a doctor and an actual prescription, so I was under medical supervision.
As the years went on my dosage increased, I very slowly became more feminine, but stayed very depressed overall. Even on antidepressants, I still have some very bad days. And I still can't help but worry if I made the right decision. I still constantly think about my small penis, but I worry if maybe I went into transition for the wrong reasons. I worry that maybe I was just supposed to fix my penis and my gynecomastia and live as a man. Pre-transition I would alternate between daydreaming about going on HRT and/or getting implants for some nice big boobs, or getting them removed altogether and trying to be a manly man.
I worry that my depression is actually a result of the HRT. That the hormones themselves are causing it, and that they're causing it because I'm not really trans. Do I like looking down the front of my dress and seeing my cleavage? Yes, usually. Do I think about having a 7" penis and having ordinary PIV sex with women? Also yes.
So what am I? Am I trans? Am I just a confused man? Am I nonbinary? Am I a gross fetishist? Should I keep going? Should I detransition ASAP?
submitted by RebeccaNobody to TransSupport [link] [comments]


2020.06.28 01:17 PradoMV96 A thorough DD on $HTBX (Heat Biologics)

What is Heat Biologics & what do they do? * Heat Biologics is a biopharmaceutical company headquartered in Morrisville, NC and has operations in San Antonio, TX * The company has a proprietary gp96 platform to activate immune responses against pathogenic or cancer antigens.
What are Their Pipeline products? * $HTBX Consists of 3 pipeline products currently in on-going clinical trials * HS-110 * HS-130 * PTX-35 * One of their pipeline products is currently under preclinic and it is meant to be a vaccine for COVID-19 * COVID-19 Vaccine
What is HS-110? * HS-110 is for the Treatment of Non-small Cell Lung Cancer * HS-110 is their first biologic product candidate in a series of proprietary ImPACT based immunotherapies designed to stimulate a patient’s own T-cells to destroy cancer. * Mechanism of Action: gp96 + CTAs * HS-110 is an off-the-shelf cell-based therapy. Their scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins * In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response in cancer patients * Their HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo) or Merck’s checkpoint inhibitor, pembrolizumab (Keytruda). The enrollment for this trial has completed with approximately 120 patients * HS-110 is near the end of Phase 2 * Link to their clinical trials
What is HS-130? * HS-130 is the first allogeneic, off-the-shelf cell therapy that delivers localized OX40-mediated co-stimulation to enhance T-cell activation. * HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein * OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses * Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fc via cell-based delivery compared to systemic administration of an OX40 agonist antibody in combination with HS-110. * Currently under Phase 1 in clinical trials * Link to their clinical trials
What is PTX-35? * PTX-35 is a potential first-in-class T-Cell co-stimulator targeting TNFRSF25 (Death Receptor 3). * Favorable safety profile was demonstrated in mice and non-human primates. * PTX-35’s development plan focuses on cancer immunotherapy. * Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”) to support development of PTX-35 and to fund a 70-patient Phase 1 clinical trial * PTX-35 has received IND clearance from US FDA and a Phase 1 trial in solid tumors has been initiated * It is currently in on-going Phase 1 trials * Link to their Current Clinical Trials
Their COVID-19 Vaccine * Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform * Such design has the potential of generating long-term immune responses and may confer immunity to different coronaviruses. * Their proprietary gp96 platform activates the human immune system to combat infectious diseases. * The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020 * Their Vaccine program is currently undergoing Preclinical trials
Recent Quarterly Financials/Business Highlights * Link to the report * Net loss attributable to Heat Biologics was approximately $6.3 million, or ($0.11) per basic and diluted share for the quarter ended March 31, 2020 compared to a net loss of $5.7 million, or ($0.17) per basic and diluted share for the quarter ended March 31, 2019 * As of March 31, 2020, the Company had approximately $26.4 million in cash, cash equivalents and short-term investments * As stated on their report: “We plan to commence preclinical testing for the COVID-19 vaccine this quarter and are finalizing our manufacturing plans, which we believe will help shorten the clinical timeline. Additionally, we are applying for grants to support clinical development of this program and are advancing collaboration discussions” & “given the strength of the data, we plan to initiate an end of Phase 2 Type B meeting with the FDA to discuss our registrational strategy.”
Risks/Negatives of the business * As found on their recent SEC Filings: * “We will need to raise additional capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate our development programs or commercialization efforts.” * “Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a de-listing of our common stock” * Nasdaq extended the bid price compliance requirement to August 31, 2020 * “Coronavirus pandemic could adversely impact our business, including our clinical trials” * “Future sales of our common stock by our existing stockholders could cause our stock price to decline” * “If we do not obtain the necessary regulatory approvals in the United States and/or other countries, we will not be able to sell our product candidates.” * “Our product candidates are in early stages of development, and therefore they will require extensive preclinical and clinical testing” * “Our COVID vaccine and diagnostic test programs are in early stages of development, and therefore they will require extensive testing and funding” * “For our ongoing clinical trial of HS‑110, we are administering our product candidates, in combination with other immunotherapy agents. Any problems obtaining the other immunotherapy agents could result in a delay or interruption in our clinical trials.” * Links to their SEC Filings: 10-Q & 10-K
Events to positively affect Q1-Q4 of 2020 * On Dec 16th 2020 $HTBX announced that the Company has dosed the first patient in the first Phase 1 clinical trial of HS-130, in combination with HS-110, for patients with advanced solid tumors refractory to standard of care. * On Jan 21st $HTBX Announced the closing of its previously announced underwritten public offering consisting of 20,000,000 shares of Common Stock together with Warrants to purchase 10,000,000 shares of Common Stock at a combined price to the public of $0.35. The gross proceeds to the Company from this offering are approximately $7,000,000 * On March 3rd 2020 $HTBX Announced that is has formally launched a program within its wholly-owned subsidiary, Zolovax, Inc., to develop a vaccine using its immune activating gp96 vaccine platform for treating or preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19. The Company also announced that it has filed a provisional patent for use of its technology platform for treating or preventing infection with the SARS-CoV-2 virus that causes coronavirus disease 2019. * On March 5th 2020 $HTBX Announced a strategic collaboration with the University of Miami Miller School of Medicine to support the development of a vaccine leveraging Heat's proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. * On March 16th 2020 $HTBX Announced that it has accepted an invitation to join the Alliance for Biosecurity, a DC-based coalition of pharmaceutical and biotechnology companies that works to ensure medical countermeasures are available to protect public health and improve the prevention and treatment of severe infectious diseases, including coronavirus. * On March 23rd $HTBX Announced that it is collaborating with the University of Miami to develop a proprietary UM COVID-19 point-of-care diagnostic test. * The new, patient-friendly test will require a simple pharyngeal throat swab to deliver on-the-spot results on a paper strip in under 30 minutes. * Preliminary research suggests the new test is specific to the novel coronavirus, with no cross-reaction to previous coronavirus subtypes. The test is designed to enable cost-effective manufacturing amenable for mass production and deployment around the world. * On April 1st 2020 $HTBX Announced the formation of its COVID-19 Advisory Board (CAB) with four key appointments: Justin Stebbing MD, PhD, Raymond Pickles, PhD, Natasa Strbo MD, DSc, and Lanying Du, PhD. * On April 29th 2020, $HTBX Announced that they continue to advance its COVID-19 vaccine program and provided an outline of its strategy as well as anticipated Q2 2020 milestones for this program. * Anticipated Q2 2020 Milestones: * Completion of development of a cell-based vaccine expressing gp96-Ig, OX40L-Ig and SARS-CoV-2 protein S * Generation of proof-of-concept data demonstrating vaccine immunogenicity in relevant preclinical models * Submission of grant applications to fund and accelerate COVID-19 vaccine development * On May 11th 2020 $HTBX Announced an update on its Phase 2 trial of its T-cell activating HS-110, in combination with Opdivo in advanced non-small cell lung cancer. * Established partnership for biomarker development with Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon * Plan to initiate Type B end of Phase 2 meeting with the FDA to discuss registration strategy * On May 27th $HTBX Announced that it is collaborating with Waisman Biomanufacturing to establish a partnership for the manufacture of Heat's COVID-19 vaccine. * Heat Biologics previously worked with Waisman to manufacture Heat's HS-130, which is currently in a Phase 1 clinical trial, and is collaborating with Waisman to support the manufacturing of its COVID-19 vaccine for expected Phase 1 trials in humans * The vaccine leverages Heat's proprietary gp96 platform to target the SARS-CoV-2 coronavirus that causes COVID-19 * On May 29th 2020 $HTBX Presented Positive Survival Benefit for HS-110 in Combination with Nivolumab in Phase 2 Lung Cancer Trial at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: * Median overall survival of 28.7 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients * Significantly greater median overall survival of 42.1 months observed in patients with injection site reaction * Planning to engage FDA for end-of-phase 2 meeting * On June 4th 2020 $HTBX Announced further progress on its COVID-19 vaccine program: * They remain on track to complete design and development of their COVID-19 vaccine in July * They expect that their gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with their partner, Waisman Biomanufacturing, in early August. * On June 8th 2020 $HTBX Announced that the FDA has cleared the Investigational New Drug application for PTX-35, developed by Heat's Pelican Therapeutics subsidiary. Pelican has near-term plans to initiate its Phase 1 clinical trial in patients with solid tumors. * On June 18th 2020 $HTBX Announced initiation of the first clinical trial site for PTX-35. Anthony Tolcher, M.D., FRCPC, a medical oncologist and co-founder of NEXT Oncology, has been appointed the lead investigator for the Phase 1 clinical trial. * On June 22nd 2020 $HTBX Announced that the first patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary
Very important documents I suggest you read * 10-Q * 10-K * Corporate Presentation done & presented this month in June
Very important Upcoming Dates & Catalysts * 2nd Quarter results is expected on August 13th 2020 * $HTBX is on track to complete design and development of their COVID-19 vaccine in July * Their gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with their partner, in early August
Target Price/Forecasts * CNN Money sets the median PT at $3.75 with a high of $5 * Yahoo Finance sets the 1yr forecast at $4 * MarketBeat sets the PT at $5 * NASDAQ sets $HTBX as a “Strong Buy” with a median PT of $3.50 with a high of $5
Final Thoughts/Comments * As I tell everyone that reads all of my DDs, please do not just see the ticker and go out and buy it without even bothering to read everything out carefully and make sure you understand everything before making a decision. * Now that I have that out of the way, my personal opinion on this is that I am surprised, pleasantly surprised! * I have known about $HTBX for a while but didnt bother with it as I was focused on others. It was brought to attention to me by my pharmacist yesterday as I was picking up my antibiotics for my Strep-Throat I am recovering from. * Anyways, as I began digging through this company and what they are about, I liked everything they have in the works as in my opinion, it is very promising, especially with all the manufacturing secured & their positive results with the early phases. * I’ll let it be known, everything that is not COVID-19 related (three pipelines) are long-holds as the one in furthest progression is at the end of Phase 2 whereas the others are in Phase 1. * Everything that is COVID-19 related is near future, as stated in upcoming catalysts * With everything said, come on Monday, I will be picking up shares in $HTBX, I feel confident in them and everything they have in the works. Especially since they are getting into developing COVID-19 testing kits. * Just remember, we are in a volatile market & any company getting involved in anything COVID-19 related are always at extra risk. Just be aware of that and other risks that I have mentioned and that are found on the SEC Filings.
Hope you guys enjoyed this thorough DD i wrote up for you ladies & gents! Remember, always extend my DD by looking into everything I have added by looking into more. I hope this DD has been able to help you guys in any way possible, even if it just provided an interesting/light read :)
Take care everyone, hope you all have a good day/weekend!
submitted by PradoMV96 to EducatedInvesting [link] [comments]


2020.06.26 02:51 Bogashi In-Depth $FRSX DD - Goes Through Everything

This was the most picked stock that you wanted DD on so here it is.
Bagholders, this is for you.
TL;DR at the end.



Catalysts:
https://finance.yahoo.com/news/foresight-enable-mass-screening-detection-111500924.html
FRSX filed a patent for fast and accurate detection of Covid-19 symptoms.

They announced a start in developing a mass screening solution for Covid-19 symptoms. The solution is based on visible-light and thermal cameras.

The company has been using FLIR thermal cameras and advanced algorithms for detection.

This new solution is more accurate and will potentially eliminate false-positive results.

The need for accurate touch-free mass screening is in very high demand all across the world and FRSX is one of the top leaders in Covid-19 detection when their new mass screening solution is made, there is potential for huge profits from potentially the U.S. Government who have recently called off Federal Screenings which will most likely be started up again due to cases spiking.


https://www.sec.gov/Archives/edgadata/1691221/000121390020015737/ea123404ex99-1_foresigh.htm
https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
FRSX announced the appointment of executive Alain Charlois as Vice President of Strategic Partnerships.

Charlois will be responsible for new business opportunities and potential partners in ADAS and autonomous driving markets in North America and Europe.
He has very extensive experience in commercializing businesses in the automotive market. Currently, he is holding leadership and business development positions in international companies such as ZF-TRW Automotive and other startups.

"Foresight’s unique vision technology has the potential to revolutionize automotive safety" said Haim Siboni, Foresight’s CEO.

Here's what the company says about Charlois:
Mr. Charlois’s unique skills and extensive industry relationships will allow us to generate additional interest in our offerings, help us identify and connect with potential corporate partners, and expand our presence in the ADAS and autonomous vehicles markets.
Charlois could be a major figure of the company and the leader of innovation in it. Expect lots of improvements to the company from him.

FRSXs technology is potentially revolutionary, of course, that is a buzz word though.


https://finance.yahoo.com/news/foresight-regains-compliance-nasdaq-minimum-120000528.html
Very recently, FRSX has regained NASDAQ compliance.

Compliance is very important for the stock price, NASDAQ compliance opens the potential for more investors and institutions to buy shares of the company.



Financials:
https://finance.yahoo.com/quote/FRSX/financials/
Surprisingly they don't have 10Q SEC forms so this is based on Yahoo Finance.
These are based on Q1 results.

Total Revenue:
- Operating revenue of $0 as compared with $0 last quarter

Operating Expenses:
- General And Administrative costs of $660,000 as compared with $803,000 last quarter.
- Salaries And Wages cost unreported.
- Selling And Marketing costs of $433,000 as compared with $266,000 last quarter.
- Research And Development costs of $2.341M as compared with $3.203M last quarter.
- Interest Income Non-Operating cost of $131,000 as compared with $235,000 last quarter.
- Other Income Expenses of $746,000 as compared with $395,000 last quarter.
Total net loss of $4.049M before tax as compared with $4.370M before tax last quarter.

Balance Sheet:
- Assets value of $19.334M.
- Liabilities And Stockholders Equities value of $19.334M.

The financials are pretty bad, the expenses are basically the same as last quarter but they haven't reported any income so it's counted as $0.



Fundamentals:
https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
Here's a description of the company:
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), founded in 2015, is a technology company engaged in the design, development and commercialization of sensors systems for the automotive industry.
Through the company’s wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both "in-line-of-sight" vision systems and "beyond-line-of-sight" cellular-based applications.
Foresight’s vision sensor is a four-camera system based on 3D video analysis, advanced algorithms for image processing, and sensor fusion.
Eye-Net Mobile’s cellular-based application is a V2X (vehicle-to-everything) accident prevention solution based on real-time spatial analysis of clients’ movement.
The company’s systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is targeting the semi-autonomous and autonomous vehicle markets and predicts that its systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform and advanced technology.

https://finance.yahoo.com/quote/FRSX/profile?p=FRSX
The companies address:
Weizmann Science Park
7 Golda Meir Street
Ness Ziona 7403650
Israel
972 7 770 9030
http://www.foresightauto.com
They have 61 full-time employees



Technicals:

Stock Info:
https://finance.yahoo.com/quote/FRSX/key-statistics/
- Usual volume of 4.01M, this is a good volume for a penny stock and allows for easy buying and selling of the stock. This also ensures that there will be movement in the stock.
- Float of 21.54M, this is the usual float for a stock of this price. The stock price is fairly easy to move which allows for the stock to rise fast but also has potential for the stock to drop fast.
- Short % of shares outstanding is 1.02%, this a very low short % which is good, the less a stock is shorted the fewer people betting on the stock falling. This also shows that the holders of the stock are confident since most people are buying long.
- Insiders hold 0.00% of the stock float, this is both good and bad.
- Institutions hold 1.84% of the stock float, this isn't that good since institutions heavily invest in companies they value as profitable.


Indicators:

Moving Averages:
- Candles are above 5 SMA, buy rating
- Candles are above 10 SMA, buy rating
- Candles are above 20 SMA, buy rating
- Candles are above 30 SMA, buy rating
- Candles are above 50 SMA, buy rating
- Candles are above 100 SMA, buy rating
- Candles are above 200 SMA, buy rating
- Candles are above VWAP, buy rating
- Candles are below HMA, sell rating
This gives FRSX a strong buy rating based on MA


Oscillators:
- Stock is neutral on RSI, hold rating
- Candles are neutral on S%K, hold rating
- Candles are below CCI, sell rating
- Candles are neutral on ADI, hold rating
- Candles are above AO, buy rating
- Stock is below Momentum, sell rating
- Stock has positive MACD levels, buy rating
- Stock is below SRI, sell rating
- Stock is neutral on WPR, hold rating
- Stock is neutral on BBP, hold rating
- Stock is neutral on UO, hold rating
This gives FRSX a sell rating based on Oscillators

FRSX has a buy rating based on indicators.


Support And Resistance:
- Support of $1.24
- Resistance of $1.95


Due to the recent fall in futures, I would stay away from buying any stock right now. Other than that here is the TL;DR


TL;DR: FRSX has massive plans for mass Covid-19 screeners. Their patent approving and in development screener will potentially eliminate false positives and have improved accuracy while also being a contact-free screener.
There is potential for an FRSX and FLIR merger since FRSX is developing Covid-19 scanners while FLIR supplies them with the thermal technologies.
The merger is just my speculation, nothing is confirmed.
Recently, Federal Covid-19 Testing has been stopped, this most likely will be turned on again since cases are spiking. There is potential for the U.S. Government to use FRSXs in development technology.
The company's financials are absolute dogshit but there is a possibility of them getting better if they gain a lot of profit from their screener sale which is still in development.
The company's headquarters are in Israel which isn't really good since it's easier to find clients when your business is mainly located in the U.S.


TL;DR;DR: This is for the bag holders
I would hold on to the stock, for now, it is not a short term play.

- Buy point is right now.
- Instant buy point is once it breaks the $1.95 resistance with some buffer.

- Sell point is if the stock goes below the $1.24 support with some buffer.
- Instant sell point if the stock goes below 200 SMA.



This is not financial advice, I'm not a financial professional. Do not buy or sell the stock due to this DD.
I'm not responsible for any loss or missed out gains due to this DD.
I do not currently hold any positions of this stock
Please trade responsibly and take days off when your portfolio is falling, just relax.
submitted by Bogashi to PennyDD [link] [comments]


2020.06.26 02:48 Bogashi In-Depth $INPX DD - Goes Through Everything

The most wanted stock was INPX so here is the DD requested.



Financials:
This is based on the most recent 10Q SEC form.
https://www.sec.gov/Archives/edgadata/1529113/000121390020011865/f10q0320_inpixon.htm#a_03

Income Statement:
- Revenue of $1.804M as compared with $1.363M last year.
- Cost of revenue of $510,000 as compared with $337,000 last year.
- Gross profit of $1.294M as compared with $1.026M last year.

Operating Expenses:
- Research and development cost of $1.334M as compared with $956,000 last year.
- Sales and marketing cost of $691,000 as compared with $633,000 last year.
- Acquisition-related costs of $28,000 as compared with $137,000 last year.
- Amortization of intangibles cost of $1.016M as compared with $812,000 last year.
- Other income expenses of $689,000 as compared with $287,000 last year.
Total net loss of $6.186M as compared with 5.150M last year. Tax benefits already applied.



Catalysts:
These are the biggest catalysts for the stock that I could find.

https://news.lenovo.com/pressroom/press-releases/lenovo-launches-internet-of-things-solutions-to-make-the-workplace-safer-during-covid-19/
Lenovo recently announced a partnership with INPX.

As Lenovo is opening their workspaces, they need monitoring which will be partly done by INPX.

INPX will be providing On Premis Contact Tracing: "Employee and visitor tracing using existing Wi-Fi network to monitor workspace zone health and enable a focused response in the event of an incident."

As Lenovo opens more workspaces for its 63,000 employees, more of INPXs service will be used which will lead to greater profit.

This also gives INPX a lot of publicity and credibility since they are working with Lenovo, a Fortune 500 company.

Here's a comment from the CEO of INPX:
Inpixon’s Indoor Intelligence technology helps organizations prepare to provide for the safety and security of their employees and visitors by leveraging their indoor data with tools that create visibility around social distancing protocols, support contact tracing efforts, and identify high priority zones for sanitizing. We’re excited to partner with Lenovo and help businesses reclaim their workplaces.

https://ir.inpixon.com/news-events/press-releases/detail/148/inpixon-to-acquire-exclusive-global-license-for-development
INPX enters into an exclusive global license agreement to develop data analysis software. They are expecting more than 400,000 users across 37 countries.

They intend to expand their software to MacOS which will further increase the number of users.
The transaction is going to be closing soon, they haven't given an exact date yet.

This will greatly increase their revenue and exposure which will in turn bring in more clients and exposure.

https://ir.inpixon.com/news-events/press-releases/detail/147/inpixon-reclaim-your-workplace-ad-campaign-launches
They have launched nationwide ads for their products and the ads have already brought in Lenovo.



Fundamentals:

https://ir.inpixon.com/news-events/press-releases/detail/148/inpixon-to-acquire-exclusive-global-license-for-development
Here is a description of the company from the company itself:
Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company's Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon's solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors.


https://finance.yahoo.com/quote/INPX/profile?p=INPX
The address of the company:
2479 East Bayshore Road Suite 195 Palo Alto, CA 94303 United States 408-702-2167 http://www.inpixon.com
They currently have 106 full-time employees



Technicals:

Overview:
https://finance.yahoo.com/quote/INPX/company360?p=INPX
- INPX has a slightly lower innovation score than the sector coming in 3 points below.
- They are hiring a lot more than the sector.
- All of their recent earnings have been lower than expected

https://www.marketwatch.com/investing/stock/inpx
- The usual volume is 7.43M, this is a good volume for a penny stock and allows for easy entry and exits of positions while also ensuring that the price will move.
- Free float of 18.55M, a stock with this low float is easier to move up but also easier to drop.
- 13.97% of the free float is shorted, this is normal for a stock, but of course, the less a stock is shorted the better.
- Market cap of $65.59M, this is a normal cap for a penny stock.


Indicators:
https://www.tradingview.com/symbols/NASDAQ-INPX/technicals/
The indicators give INPX a buy rating

Candles are above 50 SMA, the stock is in a recent upward trend
Candles are above 100 SMA, the stock is in a daily upward trend
Candles are below 200 SMA, the stock is in an overall downward trend

If the candles break above the $2.22 resistance the stock will be supported by the new $2.22 support which will put the stock in an upward trend.

Overall INPX is a solid buy with many catalysts and indicators that support the stock.
There is a lot of potential for the company, especially with all the recent news.

The buy point for me is when the stock goes above the $2.22 resistance.
The instant buy point for me is when the stock goes above the 200 SMA at $3.



This is not financial advice, I'm not a financial professional, Do not buy this stock just because of this DD. I'm not responsible for any losses that occur from this DD.
I currently do not hold any shares of this stock.
submitted by Bogashi to PennyDD [link] [comments]


2020.06.25 15:04 Bogashi In Depth $FRSX DD - For The Bagholders

This was the most picked stock that you wanted DD on so here it is.
Bagholders, this is for you.
TL;DR at the end.



Catalysts:
https://finance.yahoo.com/news/foresight-enable-mass-screening-detection-111500924.html
FRSX filed a patent for fast and accurate detection of Covid-19 symptoms.

They announced a start in developing a mass screening solution for Covid-19 symptoms. The solution is based on visible-light and thermal cameras.

The company has been using FLIR thermal cameras and advanced algorithms for detection.

This new solution is more accurate and will potentially eliminate false-positive results.

The need for accurate touch-free mass screening is in very high demand all across the world and FRSX is one of the top leaders in Covid-19 detection when their new mass screening solution is made, there is potential for huge profits from potentially the U.S. Government who have recently called off Federal Screenings which will most likely be started up again due to cases spiking.


https://www.sec.gov/Archives/edgadata/1691221/000121390020015737/ea123404ex99-1_foresigh.htm
https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
FRSX announced the appointment of executive Alain Charlois as Vice President of Strategic Partnerships.

Charlois will be responsible for new business opportunities and potential partners in ADAS and autonomous driving markets in North America and Europe.

He has very extensive experience in commercializing businesses in the automotive market. Currently, he is holding leadership and business development positions in international companies such as ZF-TRW Automotive and other startups.
"Foresight’s unique vision technology has the potential to revolutionize automotive safety" said Haim Siboni, Foresight’s CEO.

Here's what the company says about Charlois:
Mr. Charlois’s unique skills and extensive industry relationships will allow us to generate additional interest in our offerings, help us identify and connect with potential corporate partners, and expand our presence in the ADAS and autonomous vehicles markets.

Charlois could be a major figure of the company and the leader of innovation in it. Expect lots of improvements to the company from him.
FRSXs technology is potentially revolutionary, of course, that is a buzz word though.


https://finance.yahoo.com/news/foresight-regains-compliance-nasdaq-minimum-120000528.html
Very recently, FRSX has regained NASDAQ compliance.

Compliance is very important for the stock price, NASDAQ compliance opens the potential for more investors and institutions to buy shares of the company.



Financials:
https://finance.yahoo.com/quote/FRSX/financials/
Surprisingly they don't have 10Q SEC forms so this is based on Yahoo Finance.
These are based on Q1 results.


Total Revenue:
- Operating revenue of $0 as compared with $0 last quarter

Operating Expenses:
- General And Administrative costs of $660,000 as compared with $803,000 last quarter.
- Salaries And Wages cost unreported.
- Selling And Marketing costs of $433,000 as compared with $266,000 last quarter.
- Research And Development costs of $2.341M as compared with $3.203M last quarter.
- Interest Income Non-Operating cost of $131,000 as compared with $235,000 last quarter.
- Other Income Expenses of $746,000 as compared with $395,000 last quarter.
Total net loss of $4.049M before tax as compared with $4.370M before tax last quarter.

Balance Sheet:
- Assets value of $19.334M.
- Liabilities And Stockholders Equities value of $19.334M.

The financials are pretty bad, the expenses are basically the same as last quarter but they haven't reported any income so it's counted as $0.



Fundamentals:

https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
Here's a description of the company:
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), founded in 2015, is a technology company engaged in the design, development and commercialization of sensors systems for the automotive industry.

Through the company’s wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both "in-line-of-sight" vision systems and "beyond-line-of-sight" cellular-based applications.

Foresight’s vision sensor is a four-camera system based on 3D video analysis, advanced algorithms for image processing, and sensor fusion.

Eye-Net Mobile’s cellular-based application is a V2X (vehicle-to-everything) accident prevention solution based on real-time spatial analysis of clients’ movement.

The company’s systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is targeting the semi-autonomous and autonomous vehicle markets and predicts that its systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform and advanced technology.

https://finance.yahoo.com/quote/FRSX/profile?p=FRSX
The companies address:
Weizmann Science Park7 Golda Meir StreetNess Ziona 7403650Israel972 7 770 9030http://www.foresightauto.com
They have 61 full-time employees



Technicals:
Stock Info:
https://finance.yahoo.com/quote/FRSX/key-statistics/
- Usual volume of 4.01M, this is a good volume for a penny stock and allows for easy buying and selling of the stock. This also ensures that there will be movement in the stock.
- Float of 21.54M, this is the usual float for a stock of this price. The stock price is fairly easy to move which allows for the stock to rise fast but also has potential for the stock to drop fast.
- Short % of shares outstanding is 1.02%, this a very low short % which is good, the less a stock is shorted the fewer people betting on the stock falling. This also shows that the holders of the stock are confident since most people are buying long.
- Insiders hold 0.00% of the stock float, this is both good and bad.
- Institutions hold 1.84% of the stock float, this isn't that good since institutions heavily invest in companies they value as profitable.


Indicators:

Moving Averages:
- Candles are above 5 SMA, buy rating
- Candles are above 10 SMA, buy rating
- Candles are above 20 SMA, buy rating
- Candles are above 30 SMA, buy rating
- Candles are above 50 SMA, buy rating
- Candles are above 100 SMA, buy rating
- Candles are above 200 SMA, buy rating
- Candles are above VWAP, buy rating
- Candles are below HMA, sell rating
This gives FRSX a strong buy rating based on MA


Oscillators:
- Stock is neutral on RSI, hold rating
- Candles are neutral on S%K, hold rating
- Candles are below CCI, sell rating
- Candles are neutral on ADI, hold rating
- Candles are above AO, buy rating
- Stock is below Momentum, sell rating
- Stock has positive MACD levels, buy rating
- Stock is below SRI, sell rating
- Stock is neutral on WPR, hold rating
- Stock is neutral on BBP, hold rating
- Stock is neutral on UO, hold rating
This gives FRSX a sell rating based on Oscillators

FRSX has a buy rating based on indicators.


Support And Resistance:
- Support of $1.24
- Resistance of $1.95



Due to the recent fall in futures, I would stay away from buying any stock right now. Other than that here is the TL;DR


TL;DR: FRSX has massive plans for mass Covid-19 screeners. Their patent approving and in development screener will potentially eliminate false positives and have improved accuracy while also being a contact-free screener.

There is potential for an FRSX and FLIR merger since FRSX is developing Covid-19 scanners while FLIR supplies them with the thermal technologies.
The merger is just my speculation, nothing is confirmed.

Recently, Federal Covid-19 Testing has been stopped, this most likely will be turned on again since cases are spiking. There is potential for the U.S. Government to use FRSXs in development technology.

The company's financials are absolute dogshit but there is a possibility of them getting better if they gain a lot of profit from their screener sale which is still in development.

The company's headquarters are in Israel which isn't really good since it's easier to find clients when your business is mainly located in the U.S.


TL;DR;DR: This is for the bag holders
I would hold on to the stock, for now, it is not a short term play.

- Buy point is right now.
- Instant buy point is once it breaks the $1.95 resistance with some buffer.

- Sell point is if the stock goes below the $1.24 support with some buffer.
- Instant sell point if the stock goes below 200 SMA.



This is not financial advice, I'm not a financial professional. Do not buy or sell the stock due to this DD.
I'm not responsible for any loss or missed out gains due to this DD.
I do not currently hold any positions of this stock

Please trade responsibly and take days off when your portfolio is falling.
submitted by Bogashi to pennystocks [link] [comments]


2020.06.25 14:08 Bogashi In-Depth $FRSX DD - Goes Through Everything

This was the most picked stock that you wanted DD on so here it is.
Bagholders, this is for you.
TL;DR at the end.



Catalysts:

https://finance.yahoo.com/news/foresight-enable-mass-screening-detection-111500924.html
FRSX filed a patent for fast and accurate detection of Covid-19 symptoms.

They announced a start in developing a mass screening solution for Covid-19 symptoms. The solution is based on visible-light and thermal cameras.

The company has been using FLIR thermal cameras and advanced algorithms for detection.

This new solution is more accurate and will potentially eliminate false-positive results.

The need for accurate touch-free mass screening is in very high demand all across the world and FRSX is one of the top leaders in Covid-19 detection when their new mass screening solution is made, there is potential for huge profits from potentially the U.S. Government who have recently called off Federal Screenings which will most likely be started up again due to cases spiking.


https://www.sec.gov/Archives/edgadata/1691221/000121390020015737/ea123404ex99-1_foresigh.htm
https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
FRSX announced the appointment of executive Alain Charlois as Vice President of Strategic Partnerships.
Charlois will be responsible for new business opportunities and potential partners in ADAS and autonomous driving markets in North America and Europe.

He has very extensive experience in commercializing businesses in the automotive market. Currently, he is holding leadership and business development positions in international companies such as ZF-TRW Automotive and other startups.

"Foresight’s unique vision technology has the potential to revolutionize automotive safety" said Haim Siboni, Foresight’s CEO.

Here's what the company says about Charlois:
Mr. Charlois’s unique skills and extensive industry relationships will allow us to generate additional interest in our offerings, help us identify and connect with potential corporate partners, and expand our presence in the ADAS and autonomous vehicles markets.

Charlois could be a major figure of the company and the leader of innovation in it. Expect lots of improvements to the company from him.

FRSXs technology is potentially revolutionary, of course, that is a buzz word though.


https://finance.yahoo.com/news/foresight-regains-compliance-nasdaq-minimum-120000528.html
Very recently, FRSX has regained NASDAQ compliance.

Compliance is very important for the stock price, NASDAQ compliance opens the potential for more investors and institutions to buy shares of the company.


Financials:
https://finance.yahoo.com/quote/FRSX/financials/
Surprisingly they don't have 10Q SEC forms so this is based on Yahoo Finance.
These are based on Q1 results.

Total Revenue:
- Operating revenue of $0 as compared with $0 last quarter

Operating Expenses:
- General And Administrative costs of $660,000 as compared with $803,000 last quarter.
- Salaries And Wages cost unreported.
- Selling And Marketing costs of $433,000 as compared with $266,000 last quarter.
- Research And Development costs of $2.341M as compared with $3.203M last quarter.
- Interest Income Non-Operating cost of $131,000 as compared with $235,000 last quarter.
- Other Income Expenses of $746,000 as compared with $395,000 last quarter.
Total net loss of $4.049M before tax as compared with $4.370M before tax last quarter.

Balance Sheet:
- Assets value of $19.334M.
- Liabilities And Stockholders Equities value of $19.334M.

The financials are pretty bad, the expenses are basically the same as last quarter but they haven't reported any income so it's counted as $0.



Fundamentals:

https://finance.yahoo.com/news/foresight-appoints-alain-charlois-vice-120000984.html
Here's a description of the company:
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), founded in 2015, is a technology company engaged in the design, development and commercialization of sensors systems for the automotive industry.
Through the company’s wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both "in-line-of-sight" vision systems and "beyond-line-of-sight" cellular-based applications.

Foresight’s vision sensor is a four-camera system based on 3D video analysis, advanced algorithms for image processing, and sensor fusion.
Eye-Net Mobile’s cellular-based application is a V2X (vehicle-to-everything) accident prevention solution based on real-time spatial analysis of clients’ movement.

The company’s systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is targeting the semi-autonomous and autonomous vehicle markets and predicts that its systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform and advanced technology.


https://finance.yahoo.com/quote/FRSX/profile?p=FRSX
The companies address:
Weizmann Science Park7 Golda Meir StreetNess Ziona 7403650Israel972 7 770 9030http://www.foresightauto.com

They have 61 full-time employees



Technicals:

Stock Info:
https://finance.yahoo.com/quote/FRSX/key-statistics/
- Usual volume of 4.01M, this is a good volume for a penny stock and allows for easy buying and selling of the stock. This also ensures that there will be movement in the stock.
- Float of 21.54M, this is the usual float for a stock of this price. The stock price is fairly easy to move which allows for the stock to rise fast but also has potential for the stock to drop fast.
- Short % of shares outstanding is 1.02%, this a very low short % which is good, the less a stock is shorted the fewer people betting on the stock falling. This also shows that the holders of the stock are confident since most people are buying long.
- Insiders hold 0.00% of the stock float, this is both good and bad.
- Institutions hold 1.84% of the stock float, this isn't that good since institutions heavily invest in companies they value as profitable.

Indicators:

Moving Averages:
- Candles are above 5 SMA, buy rating
- Candles are above 10 SMA, buy rating
- Candles are above 20 SMA, buy rating
- Candles are above 30 SMA, buy rating
- Candles are above 50 SMA, buy rating
- Candles are above 100 SMA, buy rating
- Candles are above 200 SMA, buy rating
- Candles are above VWAP, buy rating
- Candles are below HMA, sell rating
This gives FRSX a strong buy rating based on MA


Oscillators:
- Stock is neutral on RSI, hold rating
- Candles are neutral on S%K, hold rating
- Candles are below CCI, sell rating
- Candles are neutral on ADI, hold rating
- Candles are above AO, buy rating
- Stock is below Momentum, sell rating
- Stock has positive MACD levels, buy rating
- Stock is below SRI, sell rating
- Stock is neutral on WPR, hold rating
- Stock is neutral on BBP, hold rating
- Stock is neutral on UO, hold rating
This gives FRSX a sell rating based on Oscillators

FRSX has a buy rating based on indicators.


Support And Resistance:
- Support of $1.24
- Resistance of $1.95



Due to the recent fall in futures, I would stay away from buying any stock right now. Other than that here is the TL;DR


TL;DR: FRSX has massive plans for mass Covid-19 screeners. Their patent approving and in development screener will potentially eliminate false positives and have improved accuracy while also being a contact-free screener.

There is potential for an FRSX and FLIR merger since FRSX is developing Covid-19 scanners while FLIR supplies them with the thermal technologies.
The merger is just my speculation, nothing is confirmed.

Recently, Federal Covid-19 Testing has been stopped, this most likely will be turned on again since cases are spiking. There is potential for the U.S. Government to use FRSXs in development technology.

The company's financials are absolute dogshit but there is a possibility of them getting better if they gain a lot of profit from their screener sale which is still in development.

The company's headquarters are in Israel which isn't really good since it's easier to find clients when your business is mainly located in the U.S.


TL;DR;DR: This is for the bag holders
I would hold on to the stock, for now, it is not a short term play.

- Buy point is right now.
- Instant buy point is once it breaks the $1.95 resistance with some buffer.

- Sell point is if the stock goes below the $1.24 support with some buffer.
- Instant sell point if the stock goes below 200 SMA.



This is not financial advice, I'm not a financial professional. Do not buy or sell the stock due to this DD.
I'm not responsible for any loss or missed out gains due to this DD.
I do not currently hold any positions of this stock

Please trade responsibly and take days off when your portfolio is falling, just relax.
submitted by Bogashi to u/Bogashi [link] [comments]


2020.06.24 15:50 Bogashi In Depth $INPX DD

In-Depth $INPX DD - Goes Through Everything
The most wanted stock was INPX so here is the DD requested.



Financials:
This is based on the most recent 10Q SEC form.
https://www.sec.gov/Archives/edgadata/1529113/000121390020011865/f10q0320_inpixon.htm#a_03

Income Statement:
- Revenue of $1.804M as compared with $1.363M last year.
- Cost of revenue of $510,000 as compared with $337,000 last year.
- Gross profit of $1.294M as compared with $1.026M last year.

Operating Expenses:
- Research and development cost of $1.334M as compared with $956,000 last year.
- Sales and marketing cost of $691,000 as compared with $633,000 last year.
- Acquisition-related costs of $28,000 as compared with $137,000 last year.
- Amortization of intangibles cost of $1.016M as compared with $812,000 last year.
- Other income expenses of $689,000 as compared with $287,000 last year.

Total net loss of $6.186M as compared with 5.150M last year. Tax benefits already applied.



Catalysts:
These are the biggest catalysts for the stock that I could find.

https://news.lenovo.com/pressroom/press-releases/lenovo-launches-internet-of-things-solutions-to-make-the-workplace-safer-during-covid-19/
Lenovo recently announced a partnership with INPX.

AS Lenovo is opening their workspaces, they need monitoring which will be partly done by INPX.
INPX will be providing On Premis Contact Tracing: "Employee and visitor tracing using existing Wi-Fi network to monitor workspace zone health and enable a focused response in the event of an incident."

As Lenovo opens more workspaces for its 63,000 employees, more of INPXs service will be used which will lead to greater profit.
This also gives INPX a lot of publicity and credibility since they are working with Lenovo, a Fortune 500 company.

Here's a comment from the CEO of INPX:
Inpixon’s Indoor Intelligence technology helps organizations prepare to provide for the safety and security of their employees and visitors by leveraging their indoor data with tools that create visibility around social distancing protocols, support contact tracing efforts, and identify high priority zones for sanitizing. We’re excited to partner with Lenovo and help businesses reclaim their workplaces.


https://ir.inpixon.com/news-events/press-releases/detail/148/inpixon-to-acquire-exclusive-global-license-for-development
INPX enters into an exclusive global license agreement to develop data analysis software. They are expecting more than 400,000 users across 37 countries.
They intend to expand their software to MacOS which will further increase the number of users.

The transaction is going to be closing soon, they haven't given an exact date yet.

This will greatly increase their revenue and exposure which will in turn bring in more clients and exposure.


https://ir.inpixon.com/news-events/press-releases/detail/147/inpixon-reclaim-your-workplace-ad-campaign-launches
They have launched nationwide ads for their products and the ads have already brought in Lenovo.



Fundamentals:

https://ir.inpixon.com/news-events/press-releases/detail/148/inpixon-to-acquire-exclusive-global-license-for-development
Here is a description of the company from the company itself:
Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company's Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon's solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors.

https://finance.yahoo.com/quote/INPX/profile?p=INPX
The address of the company:
2479 East Bayshore Road Suite 195 Palo Alto, CA 94303 United States 408-702-2167 http://www.inpixon.com
They currently have 106 full-time employees



Technicals:

Overview:

https://finance.yahoo.com/quote/INPX/company360?p=INPX
- INPX has a slightly lower innovation score than the sector coming in 3 points below.
- They are hiring a lot more than the sector.
- All of their recent earnings have been lower than expected

https://www.marketwatch.com/investing/stock/inpx
- The usual volume is 7.43M, this is a good volume for a penny stock and allows for easy entry and exits of positions while also ensuring that the price will move.
- Free float of 18.55M, a stock with this low float is easier to move up but also easier to drop.
- 13.97% of the free float is shorted, this is normal for a stock, but of course, the less a stock is shorted the better.
- Market cap of $65.59M, this is a normal cap for a penny stock.


Indicators:

https://www.tradingview.com/symbols/NASDAQ-INPX/technicals/
The indicators give INPX a buy rating

Candles are above 50 SMA, the stock is in a recent upward trend
Candles are above 100 SMA, the stock is in a daily upward trend
Candles are below 200 SMA, the stock is in an overall downward trend

If the candles break above the $2.22 resistance the stock will be supported by the new $2.22 support which will put the stock in an upward trend.



Overall INPX is a solid buy with many catalysts and indicators that support the stock.
There is a lot of potential for the company, especially with all the recent news.

The buy point for me is when the stock goes above the $2.22 resistance.
The instant buy point for me is when the stock goes above the 200 SMA at $3.



This is not financial advice, I'm not a financial professional, Do not buy this stock just because of this DD. I'm not responsible for any losses that occur from this DD.
I currently do not hold any shares of this stock.
submitted by Bogashi to pennystocks [link] [comments]


Couple Secretly Share Most Vulnerable Moments - YouTube How to Create and Join Yahoo Groups How to Find People on Yahoo - YouTube Yahoo - YouTube Yahoo CEO Marissa Mayer Talks Verizon Deal and Her Future at the Company

My Yahoo

  1. Couple Secretly Share Most Vulnerable Moments - YouTube
  2. How to Create and Join Yahoo Groups
  3. How to Find People on Yahoo - YouTube
  4. Yahoo - YouTube
  5. Yahoo CEO Marissa Mayer Talks Verizon Deal and Her Future at the Company
  6. How to Use Yahoo Finance - YouTube
  7. YouTube

Basic resources that yahoo finance offers. Future videos will now be posted in new channelhttps://www.youtube.com/channel/UCFCTutEm98uUFO3Q5-rHUdw/ July 25 -- Marissa Mayer, chief executive officer at Yahoo, discusses Verizon's $4.83 billion acquisition of Yahoo's web business, how she envisions her role at the new company, the legacy of ... In this tutorial you will learn how to find people on Yahoo. Don't forget to check out our site http://howtech.tv/ for more free how-to videos! http://youtub... Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. SUBSCRIBE for more! 👉http://bit.ly/SUBSCRIBEjubilee 👈 Be in our videos: https://www.jubileemedia.com/casting Check out Dia on IG: https://www.instagram.com/d... Select your yahoo profile and email address. Type the code and continue. And here you will have successfully created your group in yahoo. You can begin inviting people to join your new group. Think about what we do every day: we communicate; we take pictures of our friends, our pets, our kids ... we check sports scores and stock quotes; we read th...